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ABBREVIATIONS 
5-HT1B – 5-hydroxytryptamine (serotonin) receptor 1B 
5-HT1D – 5-hydroxytryptamine (serotonin) receptor 1D 
ATP1A2 – Gene that encodes the catalytic α2 subunit of a glial and neuronal sodium–
potassium pump 
CACNA1A – Gene that encodes P/Q voltage-dependent calcium channel  
Cav2.2 – N-type calcium channel α1B subunit  
CI – Confidence interval 
CGRP – Calcitonin gene-related peptide receptor antagonists 
CSD – Cortical spreading depression 
DNA – Deoxyribonucleic acid 
EDTA – Ethylenediaminetetraacetic acid 
EGC – Estonian Genome Center 
ENH1 – Enigma homologue 1 
FHM – Familial hemiplegic migraine 
GABA – Gamma-aminobutyric acid 
GWAS – Genome-wide association study 
Hcy – Homocysteine  
ICHD – The International Classification of Headache Disorders, 3rd edition 
IGV – Integrative Genomics Viewer 
MA – Migraine with aura 
MAF – Minor allele frequency 
MO – Migraine without aura 
MTHFR – Methylenetetrahydrofolate reductase gene 
Nav1.7 – Voltage-gated sodium channel 
NSAIDs – Non-steroidal anti-inflammatory drugs 
OR – Odds ratio 
PCR – Polymerase chain reaction 
PCR-RFLP – PCR-restriction fragment length polymorphism 
PEPD – Paroxymal extreme pain disorder 
PKCε –Protein kinase C epsilon 
PRKCE – Protein kinase C, epsilon gene 
PDLIM5 – PDZ and LIM domain protein 5 gene  
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RR – Relative risk 
SCN1A – Gene that encodes neuronal voltage-gated sodium channel Nav1.1 
SCN9A – Gene that encodes neuronal voltage gated sodium channel Nav1.7 
SNARE – SNAp (Soluble NSF Attachment Protein) REceptor 
SNP – Single nucleotide polymorphism, 
SNV – Single nucleotide variation 
TCA – Tricyclic antidepressants 
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 ABSTRACT 
Identifying common and novel variants in migraine genetic predisposition 
Migraine is an episodic brain disorder that is characterized by recurrent pain. 
Etiology of migraine is extremely complex; most likely caused by combination of 
genetic and environmental risk factors.  
 The aim of the thesis is to examine the role of MTHFR polymorphisms 
rs1801131 and rs1801133 as risk factors for pediatric migraine; also in migraine 
subtypes – migraine with aura (MA) and without aura (MO). Second part involved 
exome sequencing of two family trios to discover novel genetic risk factors for 
migraine. 
 Candidate gene study of MTHFR did not reveal any statistically significant 
results. Exome sequencing revealed three novel variants that could precipitate 
migraine. PDLIM5, PRKCE and SCN9A all affect voltage-gated channels. Mutations 
in those genes could increase neuronal hyperexcitability and neurotransmitter release, 
which in turn has been associated with pain and visual aura.  
 
Migraine; MA; MO; exome sequencing. CERCS code: B790 Clinical genetics. 
 
ABSTRAKT 
Sagedased ning haruldased variandid migreeni geneetilises põhjuslikkuses 
 Migreen on episoodiline häire, mida iseloomustavad perioodilised peavalud. 
Migreeni etioloogia on äärmiselt kompleksne, suurima tõenäosusega põhjustatud 
geneetiliste ning keskkonna riskifaktorite koosmõjust.  
 Magistritöö eesmärgiks oli uurida MTHFR polümorfismide rs1801131 ja 
rs1801133 rolli migreeni tekkes; seda ka migreeni alagruppides – auraga migreen 
(MA) ning aurata migreen (MO). Teiseks eesmärgiks oli leida uusi geneetilisi 
riskifaktoreid, sekveneerides kahe perekonna-trio eksoomid.  
 MTHFRi kandidaatgeeni uuring ei näidanud statistiliselt olulist seost 
migreeniga. Eksoomi sekveneermine avaldas kolm varianti, mis võiksid osaleda 
auraga migreeni tekkes. PDLIM5, PRKCE kui ka SCN9A mõjutavad voltaaž-
tundlikke kanaleid. Mutatsioonid nendes geenides võivad põhjustada liigset 
neuronaalset aktiivsust ja neurotransmitterite vabanemist, mida on varasemalt 
seostatud valu ja visuaalse auraga.  
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Migreen; MA; MO; eksoomi sekveneermine. CERCS kood: B790 Kliiniline 
geneetika. 
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INTRODUCTION 
Migraine is complex disabilitating primary headache disorder, which affects 
~15% of the world’s population. The headache attacks vary in frequency, severity and 
duration, lasting from 4 hours to 72 hours. International Headache Society has 
classified two main subtypes for migraine, migraine with aura and migraine without 
aura. Migraine with aura affects 1/3 of migraineurs (migraine sufferers) and is 
described by visual and sensory disturbances an hour before headache attack. 
Migraine without aura comprises ~70% of the migraine population. The Global 
Burden of Disease Survey (2013) declared migraine as 6th cause for disability in the 
world, 4th in Estonia.  
Twin studies have indicated that migraine has a genetic background as 50% of 
migraineurs have a first-degree relative also suffering from this disorder. A large 
number of candidate gene, linkage and genome-wide association studies have been 
done to identify causative gene/genes for migraine, as migraine has been stated to be 
an inherited disorder. However, only a small part of identified genes has been 
significantly and reproducibly associated with migraine.  
The aims of this master thesis are:  
• to investigate the role of two MTHFR polymorphisms rs1801131 (A1298C) 
and rs1801133 (C677T) as migraine risk factors; 
• to examine the role of two previously mentioned polymorphisms in migraine 
subtypes; 
• to identify novel mutations for migraine predisposition by sequencing 
whole-exomes of two family trios, one diagnosed with migraine with aura, 
another with migraine without aura. 
The review of literature in this thesis focuses on migraine’s clinical description, 
pathophysiology and etiology, especially on genetic risk factors. The experimental 
part concentrates on candidate gene analysis as well as whole-exome sequencing to 
identify genes that could possibly confer to migraine susceptibility.  
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1. REVIEW OF LITERATURE 
1.1. What is migraine? 
Migraine is a common neurological disorder that affects 10–20% of the world’s 
population (Leonardi et al., 2005, Haut et al., 2006). It is mainly characterized by a 
headache attack that varies in frequency, intensity and duration, but may also be 
accompanied by nausea and/or vomiting, and photo- and phonophobia (Vries et al., 
2009). It has a significant influence on one’s quality of life, being a major reason for 
missing school- or workdays, for decreased social involvement, for increased 
complexity in performing general cognitive tasks, etc. (Victor et al., 2009, Sarrouilhe 
et al., 2014). According to the Global Burden of Disease Survey (2013), migraine has 
become the sixth-highest cause of disability worldwide and is rated as the third most 
prevalent disorder. In Estonia, migraine is the fourth (same rank in Latvia and 
Lithuania) cause for years lived with disability after a major depressive disorder, back 
pain and hearing loss (Global Burden of Disease Survey, 2013).  
According to the International Classification of Headache Disorder (ICHD, 2013), 
migraine is subdivided into two main categories: migraine with aura and migraine 
without aura. Migraine with aura (MA) is described as a recurring headache preceded 
by transient focal neurological symptoms (aura). Migraine without aura (MO) is 
characterized by recurrent headache attacks lasting 4–72 hours (Bhaskar et al., 2013). 
MA and MO have been identified as two separate disorders (Russell et al., 2002, 
Ferrari et al., 2015). 
The etiology of migraine is extremely complex and it is believed to be a 
combination of environmental and genetic risk factors (Lin et al., 2015). 
1.1.1. Migraine phases 
Migraine is divided into 4 phases: prodrome, aura, headache and postdrome. Most 
migraineurs (migraine sufferers) experience one or more phases, but experiencing any 
one certain phase is not necessary for the diagnosis of migraine. Aura phase does not 
occur in patients diagnosed with MO (Anonymous, 1995).  
A majority of patients (~60%) with migraine also experience a premonitory 
phase, also known as the prodrome phase, which may occur in the 24–48 hours prior 
to the headache. This could be a warning sign for patients for the upcoming migraine 
episode. These symptoms include fatigue, cognitive change, irritability, depression 
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etc. (see Figure 1 for more symptoms) (Waldman, 2011, ICHD, 2013, Burstein et al., 
2015).  
Approximately 40–60 minutes before the headache attack, patients diagnosed with 
MA experience transient focal neurological aura symptoms (Waldman, 2011, Ferrari 
et al., 2015). They are most frequently visual and occur in more than 90% of patients 
diagnosed with MA (Waldman, 2011, ICHD, 2013). Visual disturbances may include 
flashing lights (photopsia), zigzag castellations, objects distorted in shape and size, 
and partial loss of sight (scotoma) (see Supplement 1). These symptoms are all 
caused by the unusual activity in the parietal and occipital cortex (primary visual 
cortex) or the associated areas (Ekbom, 1993, ICHD, 2013). 
The next most common symptoms are sensory disturbances. This aspect of aura 
may cause the “pins and needles” (tingling) sensation that moves slowly from the 
point source affecting mainly hands, face and/or tongue, but also may affect the whole 
body. It may also cause numbness (Waldman, 2011, ICHD, 2013). 
Less frequent are speech disturbances. These include difficulty in finding words 
and/or understanding them, concentration difficulties, or confusion (ICHD, 2013). 
Aura lasts less than 60 minutes (typically 20–30 minutes) (ICHD, 2013). 
Migraine headache is usually quite severe, throbbing and is commonly, but not 
always, unilateral (it may fluctuate between sides or become generalized) (Kojić and 
Stojanović, 2013). It may occur during the day but it is not unusual to wake up with a 
headache. Pain is often accompanied with nausea or even vomiting, patients are 
sensitive to light and sound, and feel generally weak (MacGregor, 1999). This makes 
migraineurs seek out a dark room. Pain might decrease after vomiting and sleep 
typically terminates it (Elkbom, 1993). The headache lasts from 4 hours to 72 hours 
(Bhaskar et al., 2013).  
Postdrome phase (resolution phase) is like a recovery phase. The headache is 
gone, but feeling normal could take hours or even days. Patients have illustrated it 
with the “headache hangover” feeling (Ng-Mak et al., 2011). Sufferers often believe 
that the symptoms are the result of the medication that was taken to treat migraine, 
but it could also be due to the migraine attack. Postdromal symptoms occur in the 
majority of patients and include lower or higher mood levels, physical weakness, 
fatigue and decreased concentration (Ng-Mak et al., 2011, Charles, 2013).  
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Figure 1. Four phases of migraine and symptoms during each phase (Figure obtained from 
migrainebuddy.com).  
1.1.2. Migraine with aura (MA) 
Migraine with aura, also known as classic migraine, is mainly characterized by 
transient neurological aura symptoms that typically occur before headache, but in rare 
cases also may not develop until the headache phase. This migraine subtype affects 
~30% of all migraine patients (Vries et al., 2009, Goadsby, 2012, ICHD, 2013).  
The main symptoms for aura are visual, sensory and speech disturbances. These 
symptoms last for 20–30 minutes and typically end right before headache (ICHD, 
2013).  
The duration of the headache episode in patients with MA is typically 6–8 hours 
(Zupping, 1998).  
1.1.3. Migraine without aura (MO) 
Migraine without aura, also known as common migraine, is characterized by a 
throbbing aching headache that may be accompanied by nausea, vomiting etc. 
Patients without aura do not experience focal neurologic disturbance prior to the 
headache (Rowland, 1995). This subtype accounts for two thirds of migraine patients 
(ICHD, 2013).  
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Headache normally starts during the day or right after waking up. During the 
following several hours, the pain increases. Pain is unilateral with a pulsating quality. 
Any head movement, noises and smells can increase headache (Zupping, 1988). 
Severe headache, together with nausea or insensitivity to external stimuli, make 
patients look for a dark space (Zupping, 1998). Pain lasts longer than in patients with 
MA, lasting from 4-72 hours (MacGregor, 1999).  
1.1.3.1. ICHD-III diagnostic criteria for migraine 
The first edition of the International Classification of Headache Disorders 
(ICHD) was published already in 1988 and consisted of 165 diagnoses (Levin, 2008). 
Currently, the 3rd edition of the ICHD (2013) is in use.  
The diagnosis of migraine is based on the patient’s recollection of their 
previous medical history, a review of symptoms, family history, and a neurological 
and physical examination by a physician. If all other disorders and diseases are ruled 
out, the doctor makes a diagnosis according to the ICHD (see Table 1 for diagnosis 
criteria for MA and MO) (Levin, 2008). 
 
Table 1. ICHD-III diagnostic criteria for both migraine subtypes (ICHD, 2013). 
Diagnostic criteria for MA Diagnostic criteria for MO 
A. At least two attacks fulfilling criteria B and C A. At least five attacks fulfilling criteria B–D 
B. One or more of the fully reversible aura B. Headache attacks lasting 4–72 hours 
     symptoms:      (untreated or unsuccessfully treated) 
1. visual 
 
  C. Headache has at least two of the following 
2. sensory 
 
       four characteristics:  
3. speech and/or language 1. unilateral location    
4. motor 
 
  2. pulsating quality    
5. brainstem   3. moderate or severe pain intensity  
6. retinal 
 
  4. aggravation by or causing avoidance 
C. At least two of the following four     of routine physical activity 
    characteristics:       (e.g. walking or climbing stairs) 
1. at least one aura symptom spreads D. During headache at least one of the 
    gradually over 5 min and/or two or     following:    
    more symptoms occur in succession 1. nausea and/or vomiting  
2. each individual aura symptom lasts 2. photophobia and phonophobia  
    5–60 minutes   E. Not better accounted for by another 
3. at least one aura symptom is     ICHD-3 diagnosis     
    unilateral   
 
    
4. the aura is accompanied, or followed 
       within 60 minutes, by headache 
   D. Not better accounted for by another     
      ICHD-3 diagnosis, and transient     
      ischaemic attack has been excluded     
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1.2. Migraine triggers 
A trigger is any factor that on exposure or withdrawal causes the development of 
migraine attack. Migraine can be triggered by several environmental factors. 
Activators can be certain types of food or beverages, weather, visual, olfactory or 
acoustic stimuli, but stress, hormones and sleep are the most common (Zupping 1988, 
Kojić and Stojanović, 2013).  
Stress is the most common migraine-provoking factor. In addition to triggering 
migraine, stress can also make migraine attacks worse, make them longer in duration 
or make them more frequent. Some people have reported that they get a headache 
when stress is decreasing. This is called the “weekend headache”, as people have 
ended their stressful workweek and are relaxing. A definite reason explaining why 
stress causes migraine has not yet been confirmed, but it is believed that the release of 
peptides that make blood vessels expand and become inflamed might be the source 
(Nattero et al., 1989). 
It has been stated that some patients have a migraine attack after eating or 
drinking certain things. For example, the most common dietary cause is red wine. 
Tannins and the phenolic flavonoid components of red wine have been linked to the 
trigger of migraine attacks through their interaction with the metabolism of certain 
monoamines, as well as their capacity to mobilize serotonin (Ekbom, 1993, 
Krymchantowski and da Cunha Jevoux, 2014). Another compound suggested as a 
possible migraine trigger is phenylethylamine, which is found in chocolate (Diamond 
and Marcus, 2008). 
A handful of migraine patients have said their migraine is provoked by flickering 
lights, loud and persistent noise, or inhalation of specific fumes or odours (Ekbom, 
1993).  
 In prepubescent children, the frequency of migraine is higher in boys than in 
girls. During and after puberty, more and more women start having migraine (Genzini 
et al., 2015). It has been reported that migraine is two to three times more common in 
women, during their reproductive years, than in men of a similar age, which could 
indicate that female sex hormones play a role in migraine. Hormones have an effect 
on frequency, severity and type of migraine. The fundamental mechanisms for sex 
hormones in migraine have so far eluded researchers (Bhaskar et al., 2013, Gasparini 
et al., 2013, Faria et al., 2015).  
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1.3. Heritability 
Heritability has shown to play a big role in migraine: twin and family studies have 
demonstrated that ~50% of patients with migraine have a first-degree relative who 
also suffers from migraine (Ashina et al., 2012, Persico et al., 2015). Among patients 
with MA, the relative risk (RR) of a recurrence of MA in the family is 3.8, and among 
patients with MO, the RR is 1.9 (Russell et al., 1996).  
Previous large population-based studies have concluded that both migraine 
subtypes are multifactorial inherited disorders, that are most probably caused by a 
combination of genetic and environmental risk factors (Ekbom, 1993, Russell et al., 
2002, An et al., 2013). Svensson et al. (2002) reported that during childhood and 
adolescence, the occurrence of migraine is mainly caused by genetic factors, whereas 
in adulthood, environmental factors seem to have an increased effect. Heritability 
studies in population-based twin cohorts have indicated that the heritability varies 
between 0.34 and 0.57 (in the overall migraine population; heritability value of 1 
implies complete regulation by genetic factors) (Mulder et al., 2003). The heritability 
in migraine subtypes is 0.65 for MA (Ulrich et al., 1999) and 0.61 for MO (Gervil et 
al., 1999).  
1.4. Migraine in childhood 
Migraine has a great negative influence on the physical and mental health of 
children, which also influences their school performance, family and social life, as 
well as their quality of life. Headaches, including migraine, have a much bigger 
destructive consequence on children than for example, back pain, abdominal pain, etc. 
(Rocha-Filho and Santos, 2014, Casucci et al., 2015).  
The incidence of migraine has increased notably over the last decade, as the 
estimated prevalence of migraine in the pediatric population is approximately 8% 
(Rocha-Filho and Santos, 2014, Casucci et al., 2015). The incidence for this disorder 
accounts for 3% in preschool years, increasing to 4–11% in elementary school and 
reaching up to 23% during high school years. The mean age of onset is 7 years for 
boys and 11 years for girls (Genzini et al., 2015). Genzini et al. (2015) found in their 
study that prepubescent children were three times less likely to experience aura than 
adolescents, and the average age of reporting aura was 13.1 years. 
Migraine headache in children and adolescents is often bilateral and 
frontotemporal. If pain is occipital, it requires immediate attention, as it is extremely 
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rare and could be due to something else (Winner et al., 2008, ICHD, 2013). Their 
headache attacks are less frequent and shorter in duration. Migraine is often 
underdiagnosed in children and adolescents (Winner et al., 2008).  
1.5. Migraine pathophysiology 
Migraine is considered to have a multifactorial basis. Although the pathogenesis 
has not yet been completely explained, due to the extensive number of trigger factors, 
and functional and biological abnormalities of migraine, countless concepts have been 
presented that could elucidate migraine pathophysiology to some extent (Mulder et 
al., 2003, Kojić and Stojanović, 2013). 
The main mechanisms underlying migraine pathophysiology are hyperexcitability 
of the cerebral cortex, cortical spreading depression and neurovascular inflammation 
of meningeal blood vessels (Kojić and Stojanović, 2013). 
1.5.1. Neuronal hyperexcitability  
In a normally functioning neuron, neuronal excitability is caused by the 
movement of sodium (Na+) and potassium (K+) ions from one side of the membrane 
to the other. At resting membrane potential (-70 mV), voltage-gated channels for Na+ 
and K+ are closed. During the depolarization caused by the action potential (Figure 
2), when the threshold has been reached (-55mV), the sodium channels are opened, 
but potassium channels are yet not completely opened, as they have not responded to 
the polarization. During the repolarization phase, the potassium channels are 
Figure 2. Action potential phases. The opening and closing of voltage-gated channels. 
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opened, whereas sodium channels are closed. In the refractory period, the sodium 
channels are closed and inactivated, while the potassium channels continue their 
work. Eventually the potassium channels also close and sodium channel inactivation 
is stopped. The membrane potential returns to its resting state (-70 mV) (Rhoades and 
Bell, 2009). This depolarization moves along the axon of the neuron until it reaches 
the axon terminal. At the terminal, there are voltage-gated Ca2+ channels that are 
important for Ca2+ ions to enter the neuron. As soon as the nerve impulse arrives at 
the presynaptic terminal, the charge across the membrane changes, which in turn 
opens the voltage-gated calcium channels for Ca2+ ions to enter the neuron. This 
forces vesicles full of neurotransmitters to bind with the presynaptic membrane, to be 
emptied into the synaptic cleft. Presynaptic Ca2+ channels are mainly specialized in 
neurotransmitter release, due to their attachment to synaptic vesicles (Yokoyama et 
al., 2004).  
According to one possible theory of migraine pathophysiology, migraine and 
its symptoms may be caused by a hyperexcitable brain state (Borsook et al, 2012, 
Diamond et al., 2015). Excessive neuronal activity (hyperexcitability) is mainly 
caused by changes in the ion channels, receptors and signaling molecules (Diamond et 
al., 2015). Voltage-gated calcium and sodium channels, due to their function and 
synaptic transmission properties, are targets for several mutations that cause abnormal 
excitability in neurons. Genetic forms of chronic pain, epilepsy, cardiac arrhythmia, 
etc. are disorders/diseases that are caused by alterations in the genes coding ion 
channels (these disorders/diseases are collectively called channelopathies) (Catterall 
et al., 2008, Rhoades and Bell, 2009). Several studies in electrophysiology and 
magnetoencephalography have demonstrated that increased excitability of the brain 
cortex may precipitate migraine (Welch, 2005, Borsook et al., 2012). 
For several decades it has been implied, that neuronal hyperexcitability is 
caused by genetic factors, as 50% of migraineurs also have a first-degree relative with 
this disorder. Unfortunately, investigations into those factors causing abnormal 
excitability have been quite unsuccessful (excluding familial hemiplegic migraine) 
(Welch, 2005, Rhoades and Bell, 2009).  
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1.5.2. Cortical spreading depression (CSD) 
Cortical spreading depression (CSD), which is considered the neurological 
basis of visual aura, was first described by Aristides Leão in 1944 (Gasparini et al., 
2013, Persico et al., 2015). CSD is characterized by slow self-propagating 
depolarization waves across the cerebral cortex that proceed at the velocity of 3–5 
mm/min. It starts from the occipital cortex and propagates to the frontal cortex, after 
which pain is experienced (Ashina et al., 2012). CSD is acknowledged as the basis for 
visual aura (Gasparini et al., 2013).  
CSD has been shown to activate and sensitize the trigeminovascular system, 
that in turn starts the neural, vascular and inflammatory events that cause pain. 
However, mechanisms by which CSD activates are not well known (Kojić and 
Stojanović, 2013), but it might be set in motion by migraine triggers that enhance 
cortical neuronal network excitability (Striessnig, 2005). Experiments have shown 
that CSD, in turn, may cause the disruption of ionic gradients – triggers the outflow of 
potassium ions, hydrogen ions and neurotransmitters such as glutamate into the 
extracellular space, and sodium and calcium ion inflow into the intracellular space 
(Gasparini et al., 2013, Yan and Dussor, 2014, Burstein et al., 2015). The flow of ions 
across the plasma membrane causes depolarization, followed by a prolonged 
inhibition of neuronal activity (Bhaskar et al., 2013, Kojić and Stojanović, 2013).  
1.5.3. Genetics in migraine pathophysiology 
According to countless family and twin studies, migraine is evidently identified as 
a genetic disorder. It is a complex, inherited disorder that comprises gene–gene, gene–
environment, as well as epigenetic factors. Due to the heterogeneity of migraine 
expression and comorbid disorders, the investigation of potential genes/genomic areas 
is particularly complex as many gene variants, each with a certain amount of effect, 
together might have an impact on migraine susceptibility (Shyti et al., 2011, Bhaskar 
et al., 2013, Gasparini et al., 2013). Also, across different populations, the same genes 
do not account for the susceptibility of migraine (Gasparini et al., 2013) and it has 
been suggested that both genetic and environmental factors are determinants of MO, 
whereas MA is mainly determined by genetic factors (Ashina et al, 2012). 
Additionally, Russell and colleagues (1995) and Stewart and colleagues (1997) stated 
that migraine with aura has stronger genetic influences than migraine without aura. 
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So far, numerous linkage, candidate gene and genome-wide association 
studies (GWASs) have been used in family and case-control cohorts to identify a 
possible genetic component for migraine. Via linkage studies, three genes for familial 
hemiplegic migraine, that are all associated with ion transport or ion channel 
formation, have been isolated – CACNA1A, SCN1A and ATP1A2 (Harrington et al., 
2009). Mainly, genes involved in neurological, vascular, hormonal and mitochondrial 
functions have been examined to identify candidate genes involved in migraine 
pathological pathways. In the 1930s, Graham and Wolff suggested that the pain in 
migraine is triggered by dilated blood vessels (Ahn, 2012). One of the most 
investigated and cited genes is MTHFR, that causes accumulation of homocysteine, 
that in turn dilates cerebral vessels (Stuart et al., 2010).  
Since the first migraine GWAS was done by Anttila et al. (2010), many more 
genes have been identified (see the list of several genes identified by GWAS in 
Supplement 2) for both migraine subtypes; for migraine with aura as well as for 
migraine without aura (Ashina et al., 2012). Unfortunately, only a handful of them 
have been significantly and reproducibly associated. In 2013, Gasparini et al. stated 
that GWAS is an excellent way to identify novel genes or genomic areas linked to 
disease phenotype; however it neither detects causal variants involved at the detected 
locus, nor addresses gene function. 
1.5.3.1. Familial hemiplegic migraine (FHM) 
Familial hemiplegic migraine (FHM) is a rare subtype of migraine with aura. 
In 1910, J.K. Clarke described this disorder in a family of 4 generations in which 
hemicranial pain and associated hemiparesis was seen. FHM attacks are characterized 
by the presence of hemiparesis or hemiplegia that may or may not be accompanied by 
other aura symptoms. These symptoms, as for classic migraine, last for a maximum of 
60 minutes and are followed by a severe pulsatile headache (Joutel et al. 1994, 
Gasparini et al., 2013). 
To date, three causative genes have been connected with FHM: CACNA1A, 
ATP1A2, SCNA1A. All these genes encode proteins that are involved in ion transport 
or forming channels to organize the flow of ions from one side of the plasma 
membrane to the other (Gasparini et al., 2013).  
The CACNA1A gene, located on the chromosome 19p13, encodes a protein 
that is a pore-forming α1 subunit of neuronal Ca2.1 (P/Q type) voltage-gated calcium 
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channels. This channel regulates Ca2+ ion inflow into excitable cells and is expressed 
in neuronal tissue. A defect in this gene causes a gain of slow calcium channel 
function. This also contributes to the cause of cerebellar ataxia and epilepsy 
(Harrington et al., 2009, Gasparini et al., 2013). 
Another gene associated with FHM is ATP1A2, located on chromosome 1q23. 
This gene encodes a transporter protein that is a catalytic α2 subunit of a glial and 
neuronal sodium-potassium pump. Astrocytes are the main cells expressing this kind 
of channel. A mutation in the ATP1A2 gene causes a loss of function in the 
transporter protein (Harrington et al., 2009, Russell and Ducros, 2011).  
The third gene, located on chromosome 2q24, is SCN1A, which encodes a 
neuronal voltage-gated sodium channel. This channel is essential in the generation of 
action potential in neurons. A defective SCN1A gene causes sodium channel function 
gain. This defect has also been seen in patients with epilepsy syndrome and severe 
myoclonic epilepsy in infancy (Harrington et al., 2009, Russell and Ducros, 2011). 
Although as scientific association has been found between these genes and 
FHM, they do not account for 100% of all FHM cases. This could indicate that there 
may be an additional mutation at another location, which could cause FHM 
(Harrington et al., 2009, Gasparini et al., 2013). 
1.5.3.2. Methylenetetrahydrofolate reductase (MTHFR)  
The methylenetetrahydrofolate reductase (MTHFR) gene, located on 
chromosome 1p36, encodes a protein of the same name, which converts 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is a fundamental 
enzyme in the metabolism of folate (Liu et al., 2014). Folate, in turn, is needed for the 
conversion of homocysteine to methionine (Figure 3). The lack of dietary folate or 
decreased activity of methylenetetrahydrofolate reductase (MTHFR), which is caused 
by the common polymorphisms C677T and A1298C, is thought to cause 
accumulation of the sulfur-containing amino acid homocysteine 
(HSCH2CH2CH[NH2]CO2H) in blood plasma (Stuart et al., 2010, Liu et al., 2014). 
Patients carrying the homozygous variant of C677T, express only about 30% of the 
mean activity of the MTHFR enzyme, while the defective A1298C variant decreases 
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40% of the enzyme activity 1. The C677T polymorphism has also been stated as a risk 
factor for various cancers, coronary heart disease, depression and ischemic stroke (Liu 
et al., 2014), as well as for migraine. MTHFR has been shown as a part of the genetic 
basis for abnormally increased homocysteine levels (homocysteinemia) (Lippi et al., 
2014). 
Elevated homocysteine plasma levels are a source of endothelial cell injury, 
spontaneous trigeminal cell firing, and alteration in the coagulant properties of blood. 
Vascular theory indicates that the pain in migraine is caused by the dilation of 
cerebral vessels together with inflammation in meninges that due to trigeminal cell 
firing (Berstein and Burstein, 2012).  
Homocysteine has been implicated as part of the pathophysiology of several 
neurological disorders/diseases, such as stroke, Parkinson’s disease, epilepsy, etc. 
(Obeid et al., 2008, Liu et al., 2014). 
  
Figure 3. Metabolism of homocysteine. MTHFR – methylenetetrahydrofolate reductase. Figure 
adjusted from Lippi et al., 2014. 
 
1.6. Treatment 
Treatment for migraine is divided into acute (also known as abortive) and 
preventive (also known as prophylactic), stopping the evolving attack or stopping the 
onset of attack respectively (Sarrouilhe et al., 2014).  
Acute treatments (Table 2) mainly include triptans, which specifically target 
serotonin, and ergotamine, which is vasoconstrictor of painfully dilated cranial 
arteries (Ekbom, 1993). Triptans work as 5-HT1B and 5-HT1D receptor agonists by                                                         
1http://www.kliinikum.ee/yhendlabor/images/stories/kasiraamat/HIJ/homotssteiin%20
.pdf 
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causing vasoconstriction of cerebral vessels and prohibiting the release of 
neuropeptides. The first triptan that was specifically developed for acute migraine 
therapy was sumatriptan (in tablets, injection kits and nasal spray), although an 
additional six triptans have been developed to this day (Sheikh and Mathew, 2012, 
Diener et al., 2015). In the presence of cardiovascular diseases, triptans are 
contraindicated (Ferrari et al., 2001).  
In the last decade, another quite promising abortive drug group (calcitonin gene-
related peptide (CGRP) receptor antagonists) has been developed. These drugs 
function by inhibiting pain and inflammatory neurotransmitter release in the brain and 
brainstem. CGRP receptor antagonism has a major benefit in its lack of 
vasoconstrictive effect, which means it could also be used in patients with 
cardiovascular diseases (Sherwood and Jones, 2011).  
Migraineurs also use non-steroidal anti-inflammatory drugs, e.g. aspirin (Sarrouilhe et 
al., 2014).  
Table 2. The diverse drug groups for the acute treatment of migraine. 
ABORTIVE DRUGS 
Triptans - acts on serotonin 5-HT1B and 5-HT1D receptors on cranial blood vessels 
and inhibits inflammatory neuropeptide release 
sumatriptan 
 
eletriptan 
 
  
rizatriptan 
 
almotriptan 
 
  
zolmitriptan 
 
frovatriptan 
 
  
naratriptan 
   
  
Ergotamines - vasoconstrictor via 5-HT1B receptor, inhibiting neurotransmission by 
5-HT1D receptors 
dihydroergotamine ergotamine tartrate   
Calcitonin gene-related peptide (CGRP) receptor antagonists - works on CGRP 
receptor 
olcegepant 
 
telcagepant 
 
  
Non-steroidal anti-inflammatory drugs (NSAIDs) - block the enzyme 
cyclooxygenase from synthesizing pain and inflammation-causing lipids and 
prostaglandins. 
aspirin 
 
ibuprofen 
 
  
naproxen 
  
   
 
 Preventive treatments for migraine are used considerably less than they should 
be. Lipton and colleagues (2007) stated that more than one in four migraineurs are 
suitable for preventative therapy but a substantial portion of them have not received it. 
The purpose of this kind of treatment is to decrease the frequency and intensity of 
migraine (Sheikh and Mathew, 2012). Different types of preventive drugs are 
antiepileptic drugs, tricyclic antidepressants (TCAs), excitatory mechanism 
(glutamatergic neurotransmission, ion channel) inhibitors, etc. (See Table 3 for drugs 
used for migraine prevention) (Rizzoli, 2013, Sarrouilhe et al., 2014). Valproate and 
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topiramate are the most used antiepileptic drugs for migraine prevention, as they 
influence the activity of Na+ and Ca2+ channels, GABA-A and glutamate receptors 
(Pelzer et al., 2013). The dosing can reach the amount used in epilepsy treatment but 
is usually lower for migraine. These drugs have serious side effects (e.g. depression, 
seizures, concentration difficulties etc.) (Rizzoli, 2013). Verapamil blocks L-type 
Ca2+-channels, but on higher doses can also work on P/Q-type channels. Effectiveness 
is often reported, but might also have quite severe side effects (hypotension, increased 
risk of heart failure, bradycardia etc). Another medication, which works on voltage-
gated channels, is Lamotrigine. This medication inhibits glutamate release by 
blocking Na+ and N- and P/Q-type Ca2+ channels. This medication does not work on 
headaches, however has shown somewhat an improvement on frequency and duration 
of aura (Pelzer et al., 2013).  
 
Table 3. The diverse drug groups used for the preventative treatment of migraine.  
PREVENTIVE DRUGS 
Beta-Blockers - used for relaxing blood vessels, not clear how they prevent 
migraine 
propanolol 
 
atenolol 
 
  
timolol 
 
metoprolol 
 
  
nadolol 
   
  
Calcium channel agonists - calcium channel blockers reduce the constriction of 
blood vessels 
diltiazem 
 
nimodipine 
 
  
nifedipine 
 
verapamil 
 
  
lamotrigine 
   
  
Antiepileptics - not known how they work but thought to have an impact on 
neurotransmitters 
topimarate 
 
valproate 
 
  
Tricyclic antidepressants - have pain-relieving characteristics and may reduce 
duration and frequency 
amitriptyline nortiptyline     
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2. EXPERIMENTAL PART 
1.7. Aims of the study 
The aims of the study are:  
• to examine the role of two MTHFR polymorphisms (rs1801131 – A1298C and 
rs1801133 – C677T) as the risk factors for Estonian pediatric migraine 
population; 
• to investigate the allele and genotype frequencies of both polymorphisms in 
migraine subtypes; 
• to discover possible genetic risk factors for both migraine subtypes by 
sequencing the exomes of two family-based trios, one diagnosed with 
migraine with aura, another with migraine without aura.   
1.8. Materials and methods 
1.8.1.  Genetic analysis of the MTHFR gene in migraine 
1.8.1.1. Description of patient and control groups  
In the study, 110 pediatric migraine patients (F=62, M=48) diagnosed 
according to the International Classification of Headache Disorders were enrolled. 
They were treated in the Tartu University Hospital Children’s Clinic during the period 
2011–2016. Of these patients, 46 were diagnosed with migraine with aura and 64 with 
migraine without aura. The age of the patients varied between 5–18 years, with a 
mean age of 12.5 ± 3.1 years. Migraine patients who experience or have experienced 
comorbid conditions like cardiovascular disorders (e.g. stroke) and non-migrainous 
headaches (e.g. tension headaches) were excluded from the study. Also, patients with 
secondary causes for migraine (e.g. post-head injury headache) were excluded.  
The control samples were obtained from the Biobank of the Estonian Genome 
Center. The control group consisted of 220 randomly selected healthy individuals 
(F=124, M=96), without any kind of cerebrovascular diseases (e.g. stroke, 
hypertension) and migraine. The control group was sex-matched to the patient group 
(2:1). Also, the control groups for migraine with aura and without aura subgroups 
were randomly selected. The age of controls ranged from 18 to 45 years with an 
average of 30.1 ± 3.4 years. Genotyping for rs1801131 as well as for rs1801133 in the 
control sample was done with Illumina Human Omni 770K BeadChip in the Core 
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Laboratory of the Estonian Genome Center, University of Tartu, Estonia. Quality 
control and filtration was accomplished using IlluminaGenomeStudio 3.1 and PLINK 
1.07 software (Purcell et al., 2007).  
Migraine patients and gene donors gave informed consent to participate in this 
study, which was approved by the Research Ethics Committee of Tartu University 
(protocol nr: 233/M-19).  
1.8.1.2. DNA extraction and genotyping of the sample group 
Genomic DNA was extracted from EDTA-collected peripheral blood using the 
standard high-salt extraction method.  
Genotyping of MTHFR polymorphisms rs1801131 and rs1801133 was done 
via PCR-RFLP analysis using Hinfl and MboII restriction enzymes respectively. To 
identify the rs1801133 mutation in the MTHFR gene, the amplification of a 198 bp 
PCR fragment was done using primers: forward – 
5’TGAAGGAGAAGGTGTCTGCGGGA3’ and reverse – 
5’AGGACGGTGCGGTGAGAGAGT3’. The Hinfl restriction site causes the 198 bp 
amplicon to divide into 175 bp and 23 bp fragments. The modified protocol (Hanson 
et al., 2001) for genotyping the rs1801131 mutation was applied. For the detection of 
this MTHFR polymorphism, a 256 bp fragment was amplified using following 
primers: forward – 5’CTTCTACCTGAAGAGCAAGTC3’ and reverse – 
5’CATGTCCACAGCATGGAG3’. In carriers having 1298AA genotype, the 
digestion of the 256 bp fragment results in four fragments of 176 bp, 30 bp, 28 bp and 
22 bp, whereas the 1298CC genotype gives three fragments of 204 bp, 30 bp and 22 
bp. 
Fragments were visualized on the 2.5% agarose gel in 1x TBE buffer 
(SeaKem£ LE, Lonza) electrophoresis using ethidium bromide.  
DNA extraction and genotyping was done at Tartu University Hospital, in the 
Genetics Center.  
1.8.1.3. Statistical analysis 
The genotype frequencies of both single nucleotide polymorphisms (SNPs) 
were examined to determine whether adherence to Hardy–Weinberg equilibrium was 
present. Statistical analysis for the allele association study was carried out using the 
software PLINK 1.07 (Purcell et al., 2007), and for genotypes using software R. The 
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odds ratios with 95% confidence intervals, Fisher exact test for p-values and chi-
squared analysis were calculated using R and PLINK 1.07.  
1.8.1.4. Results 
A total of 110 migraine patients and 220 healthy controls were enrolled in the 
study. The aim of genotyping was to investigate the possibility of two MTHFR 
polymorphisms as causative mutations of migraine.  
Both genotyped SNPs – rs1801131 and rs1801133 – were in Hardy–Weinberg 
equilibrium, in the patient group, in the control group, as well as in the combined 
group. 
The allele and genotype frequencies of the studied SNPs for patients and 
controls are seen in Table 4, together with the corresponding p-values and odds ratios 
(OR) for minor allele (MAF) and genotype frequencies.  
 
Table 4. The frequencies of alleles and genotypes for both MTHFR rs1801131 and rs1801133 SNPs in 
patient and control groups. MAF – minor allele frequency; CI – confidence interval. 
MTHFR 
allele  
Cases (n=110) 
MAF 
Control group (n=220) 
MAF 
Odds ratio 
(95% CI) p-value 
677T 0.300 0.296 1.02 (0.72–1.46) 0.90 
1298C 0.341 0.277 1.35 (0.95–1.91) 0.09 
 
MTHFR 
genotype 
Cases (n=110) 
frequency 
Control group (n=220) 
frequency 
Odds ratio 
(95% CI) p-value 
677CC 0.472 0.495 0.95 (0.64-1.43) 0.839 
677CT 0.454 0.427 1.06 (0.70-1.61) 0.832 
677TT 0.073 0.077 0.94 (0.39-2.25) 1 
1298AA 0.418 0.486 0.86 (0.57-1.30) 0.531 
1298AC 0.481 0.450 1.07 (0.71-1.60) 0.757 
1298CC 0.100 0.063 1.57 (0.69-3.58) 0.282 
 
For the MTHFR rs1801131 and rs1801133 polymorphisms, there was no 
statistically significant (threshold for significance p < 0.05) difference between cases 
and controls, either among genotype nor allele frequencies. The MTHFR 1298C allele 
and 677T allele were not associated with increased risk for migraine. In addition, no 
individual genotypes of both MTHFR polymorphisms showed statistically significant 
results in distribution between cases and controls (χ2 = 2.18, p = 0.34 for A1298C and 
χ2 = 0.22, p = 0.89 for C677T). Both MTHFR mutations are common in patients, with 
frequencies of 0.300 for the 677T allele and 0.341 for the 1298C allele. 
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Similarly, the allele frequencies in the migraine with aura (MA) subtype did 
not reveal any statistically relevant associations (Table 5). The observed allele 
frequency of 1298C was more prevalent in the patient group (MAF = 0.304) 
compared to controls (MAF = 0.266). Similarly to the MA subtype, no significant 
discrepancy between either variant allele was found between the migraine without 
aura (MO) group and control group. The frequency of A1298C polymorphism in MO 
group was 0.367 and 0.285, respectively for patients and controls. The 1298C and 
677T alleles did not suggest significant overall risk for migraine subtypes. 
Table 5. The allele frequency among migraine subtypes – migraine with aura (MA) and migraine 
without aura (MO). MAF – minor allele frequency; CI – confidence interval. 
MTHFR 
allele 
MA group (n=46) 
MAF 
Control group (n=92) 
MAF 
Odds ratio  
(95% CI) p-value 
677T 0.304 0.337 0.86 (0.50–1.48)  0.586 
1298C 0.304 0.266 1.21 (0.69–2.09) 0.506 
MTHFR 
allele 
MO group (n=64) 
MAF 
Control group (n=128) 
MAF 
Odds ratio  
(95% CI) p-value 
677T 0.297 0.266 1.17 (0.73–1.87) 0.518 
1298C 0.367 0.285 1.46 (0.93–2.28) 0.102 
     
 The genotypic distribution analysis revealed an interesting observation within 
the migraine with aura subtype. The control group had the defective genotypes 
1298CC and 677CT with a higher frequency (Table 6) than patients with aura. The 
same thing was detected for the 1298AC and 677TT genotypes in the migraine 
without aura subtype. The analysis of genotype distribution of both MTHFR 
polymorphisms in migraine subtypes did not reveal their significant role (Supplement 
3) in susceptibility to migraine with aura nor migraine without aura. 
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Table 6. The genetic distribution of MTHFR C677T and A1298C genotypes in migraine with aura 
(MA) and migraine without aura. CI – confidence interval. 
MTHFR 
genotype 
MA group (n=46) 
frequency 
Control group (n=92) 
frequency 
Odds ratio  
(95% CI) p-value 
677CC 0.478 0.413 1.16 (0.61-2.18) 0.745 
677CT 0.434 0.511 0.85 (0.45-1.60) 0.637 
677TT 0.09 0.08 1.14 (0.32-4.10) 1 
1298AA 0.435 0.478 0.91 (0.48-1.72) 0.872 
1298AC 0.523 0.467 1.12 (0.61-2.06) 0.755 
1298CC 0.043 0.054 0.8 (0.15-4.28) 1 
     MTHFR 
genotype 
MO group (n=64) 
frequency 
Control group (n=128) 
frequency 
Odds ratio  
(95% CI) p-value 
677CC 0.156 0.370  0.85 (0.50–1.42) 0.598 
677CT 0.156 0.245 1.28 (0.74–2.20) 0.398 
677TT 0.021 0.052 0.80 (0.24–2.65) 1 
1298AA 0.135 0.328  0.82 (0.48–1.43) 0.583 
1298AC 0.151 0.292  1.04 (0.60–1.78) 0.891 
1298CC 0.047 0.047  2.00 (0.75–5.28) 0.196 
 Analyzing the homocysteine (Hcy) level association for either MTHFR 
polymorphism, a significant effect of the 677T allele (p = 0.03, β = 1.16, standard 
deviation = 0.54) on plasma homocysteine concentrations was seen. It appears that the 
677T defective allele affects homocysteine levels. According to the Tartu University 
Hospital United Laboratory Handbook2, Hcy levels increase with age (1–7 yrs < 7.6 
µmol/L; 7–12 yrs < 8.4 µmol/L; 12–19 yrs < 11.9 µmol/L), so the patients were 
divided into age groups corresponding to the Handbook. Following investigation into 
the Hcy levels in patient age groups, no significantly higher levels were seen in any of 
the groups compared to the reference levels described.  
   
                                                        
2http://www.kliinikum.ee/yhendlabor/images/stories/kasiraamat/HIJ/homotssteiin%20.pdf 
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1.8.2. Exome sequencing to identify novel genes for migraine 
1.8.2.1. Family with migraine with aura 
The first examined family trio consists of three members – a child and mother 
affected with migraine with aura, and a clinically healthy father. The proband also has 
aunt and grandmother who have been diagnosed with migraine (Figure 4). Both of 
her brothers have died – one due to diabetes and another due to cancer.  
 
Figure 4. Family tree of patient with migraine with aura. Individuals whose exomes were sequenced 
are marked with a light blue square. Proband is marked with an arrow. (Figure created with 
https://pedigree.progenygenetics.com/) 
 
The proband is a 36-year-old woman, who has received higher education and 
is a college lecturer. She is married and is mother to 4 children. She experienced her 
first migraine attack at the age of 15. Since age 20, headaches have been regular. In 
the first several years, the headache attacks appeared once a month, but for 
approximately 15 years, attacks are weekly (in some weeks even for 4 to 5 days). 
Headaches have become much worse in the last 10 of these years. During her first two 
pregnancies and breastfeeding (first 3–4 months), the headaches were reduced or even 
disappeared but during the last two pregnancies, the headaches returned with the same 
frequency and severity. She describes her headaches as unilateral (sides can change) 
and drilling, sharp and cutting. She also experiences prodrome symptoms (lethargy, 
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photophobia) as well as visual aura and nausea accompanying the pain. An MRI was 
done in 2005 and it did not show any abnormalities.  
She has tried number of medications, acute as well as preventative, however 
most of them have not worked as migraine relievers. She went to the emergency room 
in 2010 and in 2015 due to being unable to reduce headache with prescription drugs.  
Chocolate and wine are definite migraine triggers for her.  
The proband’s mother is a 62-year-old woman, who is currently working as a 
laboratory technician. She has been experiencing headaches since her twenties. The 
headaches were extremely severe in her youth; it took several days to recover from 
the migraine attack. Several times she could not even attend work due to the severity 
of headaches. She has also tried several medications, preventative as well as acute. 
After menopause, her attacks have reduced in severity and frequency but still occur 
once a month. 
The proband’s father is also a 65-year-old healthy man. He has retired, but still 
contributes a lot to the community of his small residential town. He takes care of his 
grandchildren and lives his life to the fullest.  
The second family trio is diagnosed with migraine without aura but as no 
significant findings were discovered in this family, the family’s medical history will 
not here be described in depth. 
1.8.2.2. The collection of blood samples and the extraction of DNA 
Two families gave their informative consent for blood extraction in order to 
discover possible risk factors for migraine. The extraction of whole venous blood was 
done in Tartu University Hospital. From each patient, 8 ml of blood was transported 
to Tartu Estonian Genome Center, where the author of the thesis extracted DNA 
following a specific high-salt extraction protocol (Supplement 4). After the 
extraction, the DNA was sent to the Core Faculty of the Estonian Genome Center for 
exome sequencing (approved by the Research Ethics Committee of Tartu University, 
protocol nr: 233/M-19).  
1.8.2.3. Exome sequencing and data annotation 
The preparation of samples and exome sequencing of the two trios was carried 
out in the Estonian Genome Center (EGC), Core Facility using a HiSeq2500 Ultra-
High-Throughput Sequencing System.  
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The purified genomic DNA’s concentration was measured with a Qubit 2.0 
Fluorometer (Life Technologies, Grand Island, California, USA). For the preparation 
of next-generation sequencing libraries, 50 ng of DNA was used for the input. The 
preparation was done according to the Illumina Nextera Rapid Capture Exome 
protocol (Illumina, San Diego, California, USA). Two family trios (6 samples) were 
indexed, pooled together and then hybridized to Nextera Coding Exome Oligos 
according to the protocol of the manufacturer. Next the library mixture was quantified 
by a Qubit 2.0 Fluorometer and validated via an Agilent 2200 TapeStation analysis 
(Agilent Technologies, Santa Clara, California, USA). The library was quantified by 
qPCR with a Kapa Library Quantification Kit (Kapa Biosystems, Woburn, USA) in 
order to optimize cluster generation. Thereafter sequencing on HiSeq2500 platform 
(Illumina, San Diego, USA) with 2 x 98 bp paired-end reads was done. Of the bases 
sequenced, 93% were above a quality of Q30. Demultiplexing was done with 
bcl2fastq2 Conversion Software v2.17 (Illumina, San Diego, California, USA) 
allowing one mismatch per 8 bp index read. The number of reads was between 45 M 
and 55 M, varying between samples. 
The annotation of exome sequencing data was done by Estonian Genome Center 
specialist M. Kals using special in-house scripts. Variant annotation is based on 
Ensembl Variation API 
(http://www.ensembl.org/info/docs/api/variation/variation_tutorial.html), determining 
the gene and transcript on which the variant is located, also the importance and 
location of variant on the protein, along with SIFT and PolyPhen-2 scores, minor 
allele frequency from 1000 Genomes Project, etc. Annotation includes information 
from other databases such as CADD-score and phyloP-score, ESP6500 and 
GenomeTrax (includes several disease databases – OMIM, HGMD, ClinVar, 
Cosmic). Also the data from whole-exome sequencing and whole-genome sequencing 
form Estonian Genome Center was added to the annotation.  
1.8.2.4. Variant prioritization 
The interpretation of data was done by the author, using the scheme shown 
below (Figure 5). The first step in cleaning up the huge data file was to discard any 
mutations of insufficient quality (e.g. HARD_TO_VALIDATE, LowQD, 
LowCoverage etc). As mother and proband were diagnosed with the disorder, all 
variants that were in the homozygous-reference state for them, were discarded. The 
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father is healthy individual without migraine, so he was the homozygous-reference. 
Since rare novel variants were being looked for, anything which had an occurrence in 
the population higher than 0.05 (according to 1000 Genome Project data – 
1000G_p3_EUR) were overlooked (mutations with no available data were included). 
The CADD-score threshold was set higher than 20. Probably/possibly damaging 
variants (according to Polyphen-2 http://genetics.bwh.harvard.edu/pph2/, SIFT scores 
http://sift.jcvi.org/, and Mutation Taster http://www.mutationtaster.org/) were all 
included. The highest SIFT score of a mutation that was included was 0.05, for 
Polyphen-2, the lowest was 0.80. Next tissue expression was studied using UniProt 
(http://www.uniprot.org/) and GeneCards (http://www.genecards.org/) databases. Any 
proteins not expressed in any part of the brain were discarded. After all these steps, 
only 37 mutations out of 92 994 remained.  
The following steps taken to reduce the number of mutations that possibly 
cause migraine included the study of protein function and the selection of possible 
variations causing migraine. Finally, the three most likely mutations were selected, 
which were then reviewed together with T. Nikopensius, Estonian Genome Center 
researcher. The alignments of three genes were visualized using Integrative Genomics 
Viewer Version 2.3.72 (IGV). 
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Figure 5. Scheme showing how the novel genes/mutations for migraine in the migraine with aura trio 
were prioritized.   
1.8.2.5. Sanger sequencing 
The IGV image interpretation was not definitive for the SCN9A mutation, 
therefore validation of this mutation was done using Sanger sequencing. The 
confirmation of the mutation in the SCN9A was carried out using self-designed 
primers (used program http://primer3.ut.ee/ developed by University of Tartu 
scientists): 5’-GGCTGGGATTGTGAATAAATG-3’ and 3’- 
AGAAGACCCTGATGCAAACAA-5’. First, the interesting part of DNA was 
amplified via a PCR reaction. The total volume of PCR mixture was 20 µl, which 
contained: 
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• 10x Hot FIREPol£ PCR buffer (Solis Biodyne, Estonia) 2 µl 
• MgCl2 (25 mM)       1.2 µl 
• dNTP (2 mM)       3 µl 
• Hot FIREPol£ DNA polymerase (Solis Biodyne, Estonia) 0.3 µl 
• Forward primer (5 µM)      1 µl 
• Reverse primer (5 µM)      1 µl 
• Deionized water (MQ)      9.5 µl 
To the PCR reaction mixture, 2 µl of DNA was added. The reaction was done in the 
Applied Biosystems Veriti 96-Well Thermal Cycle according to the program shown in 
Supplement 5. The PCR product was visualized using ethidium bromide (Supplement 
6). The product size was 304 bp. The products of PCR were sent to the Estonian 
Biocenter, Core Laboratory for Sanger sequencing.  
1.8.2.6. Results 
Exome sequencing in two family trios diagnosed with migraine were performed. 
Variant calling resulted in 84 150 – 84 282 single-nucleotide variants (SNVs) and 5 
214 – 5 318 small insertion and deletion variants (indels) in both family trios.  
As a result of exome sequencing in the migraine without aura trio, no genetic risk 
factors likely attributable to the development of migraine were discovered. However 
in the family with aura, three possible mutations that might be involved in migraine 
pathophysiology were identified – in the PDLIM5, PRKCE and SCN9A genes. As the 
sequencing quality of SCN9A was not definitive for decision-making, Sanger 
sequencing was used for validation of this variant. 
The proband is heterozygous for the PDLIM5 gene missense mutation 
rs76352571, c.1448A>G (p.His483Arg, RefSeq NM_006457), located in the 13th 
exon (Figure 6). She was also heterozygous for the missense mutation in PRKCE 
gene rs34077350, c.1688C>T (p.Thr563Met, RefSeq NM_005400), located in 12th 
exon (Figure 7). The proband’s mother was heterozygous for the same missense 
mutations rs76352571 and rs34077350. The father was reference-homozygous for 
both variations. Mutations rs76352571 in the PDLIM5 gene and rs34077350 in the 
PRKCE gene are considered as probably damaging according to the PolyPhen-2 
database; damaging by SIFT (Table 7) and disease-causing by Mutation Taster. Both 
variants rs76352571 and rs34077350 are with low frequencies. In EGC whole-exome 
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(334) database, there were only 6 and 5 additional people respectively carrying 
heterozygous genotypes. The 1000 Genome Project p3 has stated that the European 
allele frequencies for these previously mentioned variants are 0.015 and 0.008, 
respectively (Table 8).  
 
Figure 6. The results of exome sequencing. IGV picture of the PDLIM5 mutation c.1448A>G, for the 
proband, mother (both diagnosed with migraine) and father (healthy individual). 
 
 
Figure 7. The results of exome sequencing. IGV picture of the PRKCE mutation c.1688C>T for the 
proband, mother (both diagnosed with migraine) and father (healthy individual). 
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The human PDLIM5 gene (Ensembl: ENSG00000163110) encodes PDZ and LIM 
domain protein 5 (UniProt: Q96HC4), which contains a PDZ domain (100 amino 
acids) at the N-terminus and three LIM domains at the C-terminus. The SNP 
(rs76352571) is located in the second LIM domain (Figure 8) (Maturana et al., 2011).  
Figure 8. The structure of PDLIM5. PDZ domain in grey, domain with unknown function in yellow 
and LIM domains in blue. Mutation rs76352571 is located in the second LIM domain. Figure adapted 
from the InterPro webpage. 
 
The human PRKCE gene (Ensembl: ENSG00000171132) encodes a protein 
kinase C epsilon (PKCε) type enzyme (UniProt: Q02156), which is a novel isoform 
from the large PKC protein kinase family. PKCε has many similar structural features 
to as other members of the PKC family, including a C1 domain (two cysteine-rich 
motifs binding diacylglycerols), a C2-like (phospholipid-binding) domain and 
catalytic domains (C3 and C4). The SNP rs34077350 is located in the kinase/catalytic 
domain (Figure 9) (Shirai et al., 2008, Newton and Messing, 2010).  
 
Figure 9. The structure of PKCε. C1a and C1b (green) – diacylglycerol binding domain; C2-like (red) 
– phospholipid-binding domain; catalytic domain (yellow) – kinase domain. Mutation rs34077350 is 
located in the kinase domain. Figure adapted from Newton and Messing (2010). 
 
After Sanger sequencing (see previous Chapter), the missense mutation 
rs199692186, c.2969A>G (p.Tyr990Cys, NM_002977) of the SCN9A gene was 
confirmed (Figure 10). The proband and her mother were heterozygous for this 
variation, whereas her father was reference-homozygous. According to Polyphen-2, 
rs199692186 is also is considered to be probably damaging, by SIFT damaging 
(Table 7) and by Mutation Taster disease-causing. According to Estonian whole-
exome (334) sequencing data, only 2 additional people had a heterozygous genotype. 
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The allele frequency stated by the 1000 Genome Project p3 is not reported, so in EUR 
as well as global (Table 8). 
The human SCN9A gene (Ensembl: ENSG00000169432) encoding the major 
voltage-gated sodium channel (Nav1.7) alpha subunit is located in the 17th exon 
(Harrington et al., 2009).  
 
 
Figure 10. The verification of the c.2969T>C mutation in the SCN9A gene by Sanger sequencing. 
Sequencing showed the proband and her mother to be heterozygous for the loci, and father to be wild-
type homozygous. 
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Table 7. Potential candidate genes for migraine with aura. 
 
Table 8. The frequency of potential candidate genes in different populations and in Estonian exome and whole genome sequencing data. AF – 1000 Genome Project, 
global allele frequency (phase 3); EUR_AF – 1000 Genome Project, European allele frequency (phase 3); het/hom.alt.est.334.ex – count of population specific 
heterozygous/alternative homozygous genotypes based on whole-exome samples; het/hom.alt.est.2244.wg – count of population specific heterozygous/alternative 
homozygous genotypes based on whole-genome samples; ExAC_NFE_AC_het_hom – non-Finnish European population allele counts, heterozygous and homozygous 
counts; ESP_EA_GTC – European American genotype count. 
ID Gene Proband Mother Father Chromo
some 
Exon Ref/Alt Mutatio
n 
type 
Change SIFT Polyphe
n 
CAD
D 
score 
phyloP 
rs76352571 PDLIM5 het het hom_ref 4 13 A/G missense p.His483Arg 0.02 1.000 27.4 5.142 
rs34077350 PRKCE het het hom_ref 2 12 C/T missense p.Thr563Met 0.02 0.984 32 4.176 
rs199692186 SCN9A het het hom_ref 2 17 T/C missense p.Tyr990Cys 0.01 0.988 24.1 0.608 
ID Gene AF EUR_AF het.est. 
334.ex 
hom.alt. 
est.334.ex 
het.est. 
2244.wg 
hom.alt. 
est.2244.wg 
ExAC_NFE_A
C_het_hom 
ESP_EA_GTC 
rs76352571 PDLIM5 0.0039 0.015 8 0 79 0 670;666;2 GG=1/GA=85/AA=4214 
rs34077350 PRKCE 0.0015 0.008 7 0 127 1 263;263;0 TT=0/TC=16/CC=4116 
rs199692186 SCN9A . . 4 0 . . 59;59;0 CC=0/CT=9/TT=4060 
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1.9. Discussion 
Migraine is a common neurological disorder that causes millions of people serious 
health and disability problems daily. It is mainly characterized by recurrent headaches 
that in 30% of migraineurs are accompanied by aura symptoms (visual, speech and 
sensory disturbances). Twin and family studies have firmly indicated that migraine is 
a genetic disorder. Several genes using genome-wide association, candidate gene and 
linkage studies have been identified for migraine, but unfortunately only a small 
portion of them have been significantly and reproducibly associated (Waldman, 2011, 
Gasparini et al., 2013).  
The purpose of this candidate gene association study was to determine the role of 
both polymorphisms rs1801131 and rs1801133 of methylenetetrahydrofolate 
reductase (MTHFR) in the pediatric migraine population, to assess their allelic and 
genotypic effect. Also to examine whether any allele/genotype could contribute to the 
disorder’s predisposition in either migraine subtypes (migraine with aura – MA, 
migraine without aura – MO). In addition, investigate the role of homocysteine in 
migraine susceptibility. MTHFR 677T and 1298C minor alleles, as migraine risk 
factors in Estonia, have been studied once before (Lorenz et al., 2014); however the 
genotypic distribution and homocysteine levels in migraineurs have not been reported. 
MTHFR encodes 5-methylenetetrahydrofolate, which is the major carbon donor 
needed for the efficient remethylation of homocysteine to methionine. In the presence 
of A1298C or/and C677T polymorphisms, MTHFR enzyme activity is reduced. This 
in turn causes moderate hyperhomocysteinemia. It is suggested that the dysfunction of 
vascular endothelium produced by hyperhomocysteinemia influences migraine 
susceptibility, especially MA, through activating trigeminal fibers, which causes 
dilation of cerebral vessels and inflammation in meninges (Liu et al., 2010, Stuart et 
al., 2010, Liu et al., 2014). 
A number of epidemiological studies have been performed in recent years to 
investigate the association of MTHFR polymorphisms as migraine risk factors in 
different populations. Unfortunately, the results have been controversial and have not 
provided any conclusive finding (Liu et al., 2014).  
An investigation into the MTHFR A1298C and C677T minor allele frequencies 
(MAF) in pediatric migraine patients, we found that 1298C and 677T alleles are 
common in Estonian population (Table 4). This is concordant with the European 
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allele frequency stated by HapMap Project (MAF=0.358 and MAF=0.309, 
respectively). Analyzing the MAF between controls and patients showed none of the 
findings to be statistically significant. The 1298C allele was seen more frequently in 
patients than controls, however non-significantly (p = 0.09, OR = 1.35), whereas the 
677T allele almost had the same frequency in patients and controls (Table 4). These 
findings are in conflict with several studies, where the 677T variant allele has been 
found to be associated with migraine susceptibility (Samaan et al., 2011, Liu et al., 
2014, Saeedi et al, 2015) rather than the 1298C allele. Furthermore, no significant 
difference resulted when analyzing migraine subtype (MA and MO) association with 
MTHFR 1298C and 677T alleles (Table 5). 
The statistical analysis of genotypic distribution of MTHFR polymorphisms 
A1298C and C677T also revealed no significant differences between migraineurs and 
the control group. In migraine subtypes, the 1298CC and 677CT genotypes were 
more frequent in control groups than in patients with MA (Table 6). Analogous 
observation was done in the MO group, where the 1298AC and 677TT genotypes 
were highly frequent in controls (Table 6). The findings in the MA group are 
supported by the study done in the Finnish population by Kaunisto et al. (2006), who 
also found no association between migraine with aura and C677T related genotypes. 
A common polymorphism – C677T in MTHFR gene – is known to be contributing 
to increased homocysteine (Hcy) levels. In the current study, the MTHFR 677T 
variant allele was found to be nominally associated with circulating homocysteine 
levels, whereas no link between the 1298C variant allele and increased Hcy levels 
was seen. These findings are in accordance with Vohnout et al. (2011), who also 
indicated that the MTHFR 677T allele increased Hcy levels. However, analyses of the 
homocysteine levels in our patients showed no significantly higher levels of 
homocysteine in those carrying defective 677T allele was observed. This could 
indicate that 677T allele contributes to increasing Hcy level, however not enough to 
be causing hyperhomocysteinemia.  
 In conclusion, neither the MTHFR C677T nor A1298C polymorphisms, 
responsible for reduction of the MTHFR activity in homocysteine metabolism, do act 
as a genetic susceptibility factors for migraine in Estonian migraine population. These 
controversial results could be due to the small sample size or due to ethnic differences 
(An et al., 2013). 
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Since the candidate gene association studies for MTHFR did not reveal any 
significant results, and GWAS is not considered to be the holy grail for migraine 
genetics 3 , since common gene variants could only explain little of the genetic 
variance, next generation sequencing was decided to use, in order to reveal novel 
variants with the population frequency < 1%. Exome sequencing was selected over 
whole genome sequencing due to the cost and fact that coding regions could be a 
potential area for identifying rare variations in complex diseases, like migraine 
(Rudkjobing et al., 2012). To our knowledge, there have been only two previous 
investigations into migraine genetic susceptibility using whole-exome and whole-
genome sequencing (Calafato, 2011, Jiang et al., 2015). The aim of whole-exome 
sequencing was to identify possible novel variants that could, to some extent, describe 
migraine pathophysiology. 
Exome sequencing in family trio diagnosed with migraine without aura did not 
reveal any clinically significant variants. MO is said to be determined by both genetic 
and environmental factors, which could indicate that its genetic influences are less 
powerful than in MA (Russell et al., 1995, Stewart et al., 1997, Ashina et al., 2012). 
However, exome sequencing in migraine with aura trio revealed three rare 
mutations that could possibly be associated with migraine susceptibility. The proband 
and mother, diagnosed with MA, were heterozygous for all mutations (rs34077350 in 
PRKCE, rs76352571 in PDLIM5 and rs199692186 in SCN9A), whereas the father was 
reference-homozygous (a healthy individual). Since no previous studies have been 
done with the mutations found by the thesis author, only assumptions about the 
expression and function of the mutated genes could be made.  
The first mutation, rs76352571 c.1448A>G, is located in the PDLIM5 gene on 
chromosome 4q22. PDLIM5 encodes PDZ and LIM domain protein 5 (also known as 
ENH1, forwardly referred as PDLIM5), which is 595 amino acids in length with a 
molecular weight of 63.9 kDa. LIM domains at the C-terminus are 50–60 amino acid 
long double zinc finger motifs that serve as protein–protein interaction sites in 
numerous proteins (Horiuchi et al., 2006, Zhao et al., 2009). Chen and colleagues 
(2006) reported that the second LIM domain is vital for forming protein–protein 
interactions. The mutation found by the thesis author is also localized in the second 
LIM domain of the protein. The cytoplasmic PDLIM5 is expressed in various brain                                                         3 http://iasppain.org/files/Content/ContentFolders/GlobalYearAgainstPain2/HeadacheFactSheets/14-
Genetics.pdf 
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regions, particularly in the hippocampus, cortex, thalamus, hypothalamus, amygdala 
and cerebellum (Zhao et al., 2009, Newton and Messing, 2010, Maturana et al., 2011). 
The second mutation, rs34077350 c.1688C>T, is located in the PRKCE gene 
on chromosome 2p21. The PRKCE gene encodes a protein kinase C epsilon (PKCε) 
type enzyme with a molecular weight of 83.6 kDa and a length of 737 amino acids. 
PKCε is highly expressed in the brain and has been found to have an important role in 
neurotransmitter release, membrane excitability and ion channel regulation. The 
protein is mainly found in the cerebral cortex, cerebellum and hippocampus. The 
mutation is located in the Ser/Thr kinase domain (Maeno-Hikichi et al., 2003, Shirai 
et al., 2008, Newton and Messing, 2010). 
PDZ and LIM domain protein 5 is known to interact specifically with PKCε 
(Figure 11) to recruit the kinase directly to its substrate (voltage-gated calcium 
channel). The formation of kinase–substrate aggregation is the molecular basis for the 
specificity and efficiency of cellular signaling. Direct protein–protein interaction 
between the LIM domain protein and the enzyme modulates the activity of the N-type 
 
Figure 11. The gene–gene interaction between PRKCE and PDLIM5 (Figure obtained from string-
db.org). The pink connecting line indicates that the interaction is determined by experiments. 
 
voltage-gated calcium channel (Cav2.2), which is induced via the phosphorylation of 
the channel’s α1 subunit by PKCε. The forming of the PKCε-ENH1-N-type Ca2+ 
channel complex is essential for the potentiation of high voltage-activated calcium 
channels in neurons (Chen et al., 2006, Zain et al., 2012, Liu et al., 2013).  
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Studies done on protein–protein interactions have shown that the LIM domains 
have high specificity to particular sequences of other proteins, which ensures the 
effective forming of the complex (Pawson, 1998). In the presence of mutation 
rs76352571, located in the second LIM domain, the binding ability of PDLIM5 to 
PKCε could be affected, which could cause an increase in affinity towards protein 
kinase C. Arimura et al. (2004) declared that a mutation in the third LIM domain (has 
four all together) of Cypher/ZASP protein (also belonging to the Enigma subfamily 
like PDLIM5) alters the binding affinity to protein kinase C, by increasing it. 
Consequently, due to this gain-of-function, the specificity and efficiency, as well as 
the probability of binding between the kinase and Cav2.2 could also be increased to 
some extent.  
The expression of the PDLIM5 have been previously reported to be 
significantly and commonly increased in the patients with bipolar disorder, 
schizophrenia and major depressive disorder (Iwamoto et al., 2004). Several 
mutations (rs2433320, rs10008257, rs2433322) in the PDLIM5 gene have been found 
to be associated with previously mentioned major mental disorders (Horiuchi et al., 
2006, Liu et al., 2008, Zhao et al., 2009). For example, the increase in protein level in 
schizophrenia patients has been attributed to SNP rs2433320, where the A allele is 
associated with higher expression contrary to the G allele (Horiuchi et al., 2006). 
Even though, all these previously mentioned mutations seem to be associated with 
transcriptional activities, we can still hypothesize that our variation has totally distinct 
effect on the protein. It could be due to the fact that all these SNPs are located in the 
upstream region of the gene (Zain et al., 2012), whereas our variation is located 
towards the 3’ end of the protein. This could also exclude the possibility of the family 
trio suffering from one of these disorders/diseases. Unfortunately, relatively little is 
known about the biological function of the cytoplasmic LIM domains; however 
important neuronal roles (receptor trafficking, signal transduction etc.) have been 
suggested (Pawson, 1998). 
 The modulation of calcium release in the presynaptic terminal is an excellent 
regulation mechanism for releasing neurotransmitters into the synaptic cleft (Catterall, 
2011). The second identified rare mutation, rs34077350, is located in the catalytic 
domain of the PKCε enzyme. The variation in the kinase could stimulate the 
phosphorylation of the N-type calcium channel α1 subunit (Figure 12) as well as G-
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protein coupled receptors (GPCRs), as these phosphorylations are the foundation of 
considerable up-regulation of the calcium channel activity. In neurons, the inhibition 
of voltage-gated N-type calcium channels (Cav2.2) are carried out by G-protein 
coupled receptors, by decreasing the N-type channel activity by 60%. This kind of 
inhibition could be overturned by the PKC–dependent phosphorylation of GPCRs, G-
protein interaction sites on the channel, or the G-protein itself. It has been found that 
the phosphorylation of G-protein can also result in enhancement of the calcium 
current (the channel activity is increased by approximately 50%), while G-protein 
inhibition is fully antagonized (Hamid et al., 1999, Bourinet and Zamponi, 2005, 
Zamponi and Currie., 2013). 
 
Figure 12. The phosphorylation of the Cav2.2 α1 subunit by PKCε. Protein kinase C is marked in light 
blue (Catterall, 2011).  
 
 The Cav2.2 channels encoded by the single α1-subunit gene are located in the 
presynaptic nerve terminals. The N-type channels have an important responsibility to 
regulate neurotransmitter release in presynaptic neurons, as the channels are linked to 
synaptic vesicles by SNARE proteins. Chronic pain has been characterized by the 
change in the performance of the ion channels, as well as by extensive 
neurotransmitters release, which leads to a state of hyperexcitability. The up-
regulation of Cav2.2 expression has been associated with pathophysiology of pain, 
which is supported by the fact that the absence of N-type channels in mice has shown 
a decreased response to pain (Yokoyama et al., 2004, Bourinet and Zamponi, 2005, 
Chen, 2011).  
 Formation of the PKCε-ENH1-N-type calcium channel complex allows quick 
and selective modulation of calcium channel activity (Maeno-Hikichi et al., 2003). In 
the presence of the mutations rs34077350 in PRKCE and rs76352571 in PDLIM5, the 
inflow of calcium into neurons could significantly increase. This in turn could cause 
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extensive release of neurotransmitters, which has previously been associated with 
pain (Bourinet and Zamponi, 2005). Also, excessive calcium influx causes 
hyperexcitability, which has been related to cortical spreading depression (CSD), 
known to be the basis for visual aura (Gasparini et al., 2013).  
 The third mutation of interest, rs199692186 c.2969A>G, is located in the 
SCN9A gene on chromosome 2q24. SCN9A encodes the α subunit of the Nav1.7 
sodium channel protein that is expressed highly in pain-sensing neurons. Voltage-
gated sodium channels consist of a 1988 amino acid long α subunit (~260 kDa) and 
two auxiliary β subunits (~35 kDa) (Waszkielewicz et al., 2013). This channel is an 
essential component in pain perception in humans, as mutations in them cause 
functional abnormality in neurons. Changes caused by the heterozygous mutations in 
amino acids of Nav1.7 are the source of different pain-related phenotypes. Loss-of-
function mutations in Nav1.7 cause a complete incapability to perceive pain (disorder: 
congenital insensitivity to pain). Patients with these kind of mutations are unable to 
sense any form of pain, often experiencing painless fractures, burns and injuries. 
Gain-of-function mutations, on the other hand, cause attacks of severe pain, often 
with a burning quality (disorders: erythromelalgia, paroxysmal extreme pain disorder, 
small fiber neuropathy etc.). This is due to the increase of Nav1.7 channel activity 
(Raouf et al., 2010, Reimann et al., 2010). The mutation rs199692186 is located near 
the missense variation R996C that contributes to paroxysmal extreme pain disorder 
(Figure 13). Paroxymal extreme pain disorder (PEPD) is caused by a gain-of-function 
mutation and is characterized by episodes of severe perineal, periocular and 
perimandibular pain (Zorina-Lichtenwalter et al., 2016). The mutation, found by the 
thesis author, could also cause gain of function of the Nav1.7 channel in migraine.  
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Figure 13. The location of the rs199692186 mutation found by the thesis autor (marked in pink) in the 
SCN9A gene. All labelled mutations are contributing to different pain disorders. Adapted from 
Reimann et al., (2010) 
 
The rs199692186 variation in SCN9A could have a modifier effect regarding the 
enhancement of pain perception in migraine pathophysiology. To date, the role of 
SCN9A mutations in central nervous system abnormalities is unclear; however, 
mutations causing a spectrum of syndromes (PEPD, congenital insensitivity to pain 
etc.) show that Nav1.7 has a critical role in altering neuronal excitability, which in 
turn is linked to human pathologies (Raouf et al., 2010).  
All these previously discussed mutations affect, either directly or indirectly, 
voltage-gated ion channels that are known to alter neuronal excitability. Higher 
neuronal excitability has been associated with cortical spreading depression, which is 
the foundation of visual aura (Gasparini et al., 2013). Hyperexcitability in turn causes 
the excessive release of neurotransmitters that is related to pain pathophysiology 
(Bourinet and Zamponi, 2005). These findings suggest that alterations in the PDLIM5 
and PRKCE could contribute synergistically for migraine with aura pathophysiology. 
SCN9A variant in the other hand could act as a modifier effect that could likely 
increase the pain perception in migraine. These candidate genes however require 
further investigation in a larger cohort to confirm their involvement in migraine. 
In summary, whole-exome sequencing did not reveal significant variations for 
migraine predisposition in migraine without aura family trio. However, in a family 
diagnosed with migraine with aura three rare variants that could cause migraine were 
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identified. These rare probably pathogenic variants were located in the PDLIM5 
(rs76352571), PRKCE (rs34077350) and SCN9A (rs199692186) genes. Exome 
sequencing seems to be a potentially effective tool for identifying rare genes for 
migraine with aura susceptibility. 
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SUMMARY 
Migraine is a complex central nervous system disorder with approximately 1 
billion people all over the world suffering from it. Migraine is subdivided into two 
groups: migraine with aura (MA) and migraine without aura (MO). The inherited 
nature of migraine is considered as an important aspect of the disorder’s 
pathophysiology. To date only a small number of genes have been associated with 
migraine, all being common variants. However, the possibility of using next-
generation sequencing could establish genetic background for migraine with aura and 
without aura. 
Candidate gene association study done in this thesis analyzed the possibility of 
MTHFR polymorphisms rs1801131 (A1298C) and rs1801133 (C677T) as migraine 
risk factors. The study revealed no significant association between migraine and both 
MTHFR polymorphisms, so in overall migraine group as well as in migraine 
subtypes. This finding is controversial with several meta-analyses, which have found 
that 677TT genotype has significant association with migraine with aura. This 
controversy could be due to ethnic-specific effect or small sample size.  
Sequencing the exomes of a family trio (proband and mother diagnosed with 
migraine without aura, father healthy individual) revealed no clinically significant 
findings. However, in another family trio experiencing severe migraine phenotype 
(MA), three potential rare deleterious variants for migraine predisposition were 
discovered. Previous studies have not associated these genes with migraine 
susceptibility.  
The variants rs34077350 in the PRKCE gene and rs76352571 in the PDLIM5 
gene could contribute to a digenic causality for familial MA. Due to the mutation in 
second LIM domain, which has been reported to be important in the protein-protein 
interaction, the affinity towards the Ser/Thr kinase (PDLIM5 interacts with PKCε, 
which is encoded by PRKCE) could increase, and transport of the kinase to the 
voltage-gated N-type calcium channels (Cav2.2) could be with increased specificity 
and efficiency. The mutation in the PRKCE gene could in turn stimulate the 
phosphorylation of the Cav2.2 channel α1 subunit or/and G-protein coupled receptor. 
Both these previously mentioned phosphorylations increase calcium channel activity, 
which in turn leads to neuronal hyperexcitability and increase in neurotransmitter 
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release. Chronic pain has been associated with extensive neurotransmitter release 
whereas visual aura (visual disturbances) with hyperexcitability. 
Third mutation rs199692186, in the SCN9A gene could have a modifier effect on 
migraine with aura predisposition due to the gain-of function effect, which causes the 
increase in activity of Nav1.7 channel. It has been previously reported to cause severe 
pain disorders (paroxymal extreme pain disorder and primary erythermalgia), which 
are caused by gain-of-function mutations in SCN9A.  
The variations in three genes – PRKCE, PDLIM5 and SCN9A – could contribute 
to the pain and/or visual aura of MA subtype. These findings although are preliminary 
and need further investigations in bigger cohorts.    
 48 
KOKKUVÕTE 
Sagedased ning haruldased variandid migreeni geneetilises 
põhjuslikkuses 
Anna-Liisa Lorenz 
 
Migreen on kompleksne kesknärvisüsteemi häire, mis mõjutab umbes üht 
miljardit inimest üle maailma. Migreen on jaotatud kaheks alatüübiks: migreen auraga 
ja migreen aurata. Migreeni patofüsioloogia oluline osa on selle pärilikkus. Tänaseni 
on migreeni tekkega seostatud vaid väikest hulka geene ning siiani on uuritud 
peamiselt sageli esinevaid variante. Järgmise põlvkonna sekveneerimistehnoloogia 
võimaldab põhjalikumalt uurida migreeni alatüüpide geneetilist olemust ka haruldaste 
variantide tasandil.  
 Magistritöös läbiviidud assotsiatsiooniuuringu eesmärgiks oli esmalt kindlaks 
teha MTHFR geeni kahe polümorfismi rs1801131 (A1298C) ja rs1801133 (C677T) 
osa migreeni kujunemises. Kumbki MTHFRi polümorfism ei näidanud statistiliselt 
olulist seost migreeniga, seda nii migreeni üleüldises grupis kui ka migreeni 
alatüüpides. Saadud tulemus on aga vastuolus mitmete meta-analüüsidega, kus on 
leitud, et 677TT genotüübil on statistiliselt oluline seos auraga migreeni tekkes. 
Nimetatud vastuoluline leid võib olla tingitud nii etniliste taustade erinevustest kui ka 
meiepoolsest väikesest uuringugrupist. 
 Perekonna trio (emal ja lapsel diagnoositud aurata migreen, isa on terve 
indiviid) eksoomide sekveneerimine ei leidnud olulist kliinilist tähendust omavaid 
geenivariante aurata migreeniga perekonnas. Seevastu auraga migreeni (MA) 
perekonnas leiti kolm potentsiaalset haruldast deleterioosset mutatsiooni, mis võiksid 
põhjustada migreeni. Varasemalt ei ole nende geenide variante migreeniga seoses 
kirjeldatud. Mutatsioonid rs34077350 PRKCE geenis ning rs76352571 PDLIM5 
geenis võivad omada sünergistlikku mõju auraga migreeni kujunemises. PDLIM5 
teises LIM domäänis, mida on varasemalt kirjeldatud kui tähtsat domääni valk-valk 
interaktsioonis, asuva mutatsiooni tulemusena võib afiinsus Ser/Thr kinaasi (PDLIM5 
seondub PKCε kinaasiga, mida kodeerib PRKCE) suhtes suureneda ning samuti 
tõusta efektiivsus ja spetsiifilisus kinaasi transpordil voltaaž-tundliku N-tüüpi 
kaltsium kanalile. Mutatsioon rs34077350 aga PRKCE geenis võib stimuleerida 
kaltsiumkanali α1-subühiku või G-proteiini retseptori fosforüleerimist, mis põhjustab 
kaltsiumkanali aktiivsuse tõusu ja neuronite erutuvuse suurenemist. Protsessi 
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tagajärjel toimub neurotransmitterite suurenenud vabanemine. Kroonilist valu on 
varem seostatud rohkete neurotransmitterite vabanemisega ning visuaalset aurat 
(nägemishäireid) kõrgema neuronaalse aktiivsusega. 
 Kolmas mutatsioon rs199692186, mis asub SCN9A geenis võib omada 
modifitseerivat efekti auraga migreeni kujunemises. Mutatsioon võib olla gain-of-
function, mis põhjustab naatriumkanali aktiivsuse tõusu ning varasemalt on seostatud 
erinevate tugevat valu põhjustavate häiretega (nt. episoodiline kobarpeavalu). 
Variandid kolmes geenis – PDLIM5, PRKCE, SCN9A – võivad põhjustada 
migreeni eelsoodumust. Need leiud on esmased ning vajavad laialdasemaid uuringuid 
suuremates kohortides.  
    
 50 
REFERENCES 
1. Ahn A.H. 2012. The neurobiology of throbbing pain in migraine. Headache, 
52(Suppl 1): 12-14. 
2. An X.K., Lu C.X., Ma Q.L., Zhang X.R., Burgunder J.M., Lin Q. and Qu H.L. 
2013. Association of MTHFR C677T Polymorphisms with Susceptibility to 
Migraine in the Chinese Population. Neuroscience Letters, 549: 78-81. 
3. Anonymous. 1995. Migraine. Harvard Women's Health Watch, 2, p. 2 
4. Anttila V., Stefansson H., Kallela M., Todt U., et al. 2010. Genome-wide 
association study of migraine implicates a common susceptibility variant on 
8q22.1. Nat Genet, 42: 869-873. 
5. Anttila V., Winsvold B.S., Gormley P., Kurth T., Bettella F., et al. 2013. Genome-
wide meta-analysis identifies new susceptibility loci for migraine. Nature 
Genetics, 45: 912-917. 
6. Arimura T., Hayashi T., Terada H., Lee S.Y., Zhou Q., Takahashi M., Ueda K., et 
al. 2004. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters 
the binding affinity to protein kinase C. J Biol Chem. 20: 6746-6752. 
7. Ashina S., Bendtsen L, Ashina M. 2012. Pathophysiology of migraine and 
tension-type headache. Techniques in regional anesthesia and pain management, 
16: 14-18. 
8. Berstein C., Burstein R. 2012. Sensitization of the trigeminovascular pathway: 
perspective and implication to migraine pathophysiology. Journal of Clinical 
Neurology, 8: 89-99. 
9. Bhaskar S., Saeidi K., Borhani P., Amir H. 2013. Recent progress in migraine 
pathophysiology: role of cortical spreading depression and magnetic resonance 
imaging. European Journal of Neuroscience, 38: 3540-3551. 
10. Borsook D., May A., Goadsby P.J., Hargreaves R. 2012. The migraine brain: 
imaging structure and function. Oxford University Press, p. 299. 
11. Bourinet E., Zamponi G.W. 2005. Voltage gated calcium channels as targets for 
analgesics. Current Topics in Medicinal Chemistry, 5: 539-546.  
12. Burstein R., Noseda R., Borsook D. 2015. Migraine: Multiple processes, complex 
pathophysiology. The Journal of Neuroscience, 35: 6619-6629. 
13. Calafato M.S. 2011. Uncovering the role of common and rare variants in migraine. 
Doctoral Thesis. University of Cambridge.  
14. Casucci G., Villani V., d’Onofrio F., Russo A. 2015. Migraine and lifestyle in 
childhood. Neurol Sci, 36: S97-S100. 
15. Catterall W.A. 2011. Voltage-gated calcium channels. Cold Spring Harb Perspect 
Biol, 3: 1-23. 
16. Catterall W.A., Dib-Hajj S., Meisler M.H., Pietrobon D. 2008. Inherited neuronal 
ion channelopahties: New windows on complex neurological diseases. The 
Journal on Neuroscience, 28:11768-11777. 
17. Charles A. 2013. The evolution of a migraine attack – a review of recent evidence. 
Headache, 53: 413-419. 
18. Chasman D.I., Schürks M., Anttila V., de Vries B., Schminke U., et al. 2011. 
Genome-wide association study reveals tree susceptibility loci for common 
migraine in the general population. Nat Genet, 43: 695-698. 
19. Chen Y, Lai M., Maeno-Hikichi Y, Zhang J.F. 2006. Essential role of the LIM 
domain in the formation of the PKCepsilon-ENH1-N-type Ca2+ channel complex. 
Cell Singal, 18:215-224.  
20. Chen Y., Tian Q. 2011. The role of protein kinase C epsilon in neuronal signal 
transduction and neurogenic diseases. Front Med, 5: 70-76. 
21. Clarke J.M. 1910. On recurrent paralysis in migraine, with report of a family in 
which recurrent hemiplegia accompanied the attacks. Brit Med. J. 1, 1534-1538. 
 51 
22. Diamond M.L., Marcus D.A. 2008. Controversies in headache medicine: Migraine 
prevention diets. American Headache Society website.  
23. Diamond S., Cady R.K., Diamond M.L., Green M.W., Martin V. 2015. Headache 
and migraine biology and management. Elsevier Inc, p. 101-103. 
24. Diener H.C., Charles A., Goadsby P.J., Holle D. 2015. New therapeutic 
approaches for prevention and treatment of migraine. Lancet Neurol, 14: 1010-
1022. 
25. Ekbom K. 1993. Migraine in general practice. Smith-Gordon and Company 
limited, p. 36-37, 43-46. 
26. Faria V., Erpelding N., Lebel A., Johnson A., Wolff R., Fair D., Burstein R., 
Beverra L., Borsook D. 2015. The migraine brain in transition: girls vs boys. Pain, 
156: 2212-2221. 
27. Ferrari M.D., Klever M.D., Terwindt M.D., Ayata C., van den Maagdenberg 
A.M.J.M. 2015. Migraine pathophysiology: lessons from mouse models and 
human genetics. Lancet Neurol, 14: 65-80 
28. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. 2001. Oral triptans (serotonin 
5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The 
Lancet, 358:1668-1675. 
29. Freilinger T., Anttila V., de Vries B., Malik R., Kallela M., et al. 2012. Genome-
wide association analysis identifies susceptibility loci for migraine without aura. 
Nat Genet, 44: 777-782. 
30. Gasparini C.F., Sutherland H.G., Griffiths L. 2013. Studies on the 
pathophysiology and genetic basis of migraine. Gurrent genomics, 14: 300-315. 
31. Genzini J., Matar A.K., Zelnik N., Schertz M., Srugo I. 2015. Frequency of 
pediatric migraine with aura in a clinic-based sample. Headache, 56: 113-117. 
32. Gervil M., Ulrich V., Kaprio J., Olsen J., Russell M.B. 1999. The relative role of 
genetic and environmental factors in migraine without aura. Neurology, 53: 995-
999. 
33. Global Burden of Disease Study 2013 Collaborators. 2013. Global, regional and 
national incidence, prevalence and years lived with disability for 301 acute and 
chronic diseases and injuries in 188 contries, 1990-2013: a systematic analysis for 
the Global Burden of Disease Study. Lancet, 386: 743-800.  
34. Goadsby P.J. 2012. Pathophysiology of migraine. Ann Indian Acad Neurol, 15: 
15-22.  
35. Hamid J., Nelson D., Spaetgens R., Dubel S.J., Snutch T.P., Zamponi G.W. 1999. 
Identification of an integration center for cross-talk between protein kinase C and 
G protein modulation of N-type calcium channels. J Biol Chem, 274: 6195-6202. 
36. Hanson N.Q., Aras O., Yang, F. Tsai M.Y. 2001. C677T and A1298C 
polymorphisms of the methylenetetrahydrofolate reductase gene: Incidence and 
effect of combined genotypes on plasma fasting and post-methionine load 
homocysteine in vascular disease. Clinical Chemistry, 47: 661-666. 
37. Harrington M.G., Fonteh A.N., Arakaki X., Cowan R.P., Ecke L.E., Foster H., 
Hümer A.F., Biringer R.G. 2009. Capillary endothelial Na+, K+, ATPase 
transporter homeostasis and a new theory for migraine pathophysiology. 
Headache, 50: 459-478. 
38. Haut, S.R., Bigal, M.E., and Lipton, R.B. 2006. Chronic disorders with episodic 
manifestations: focus on epilepsy and migraine. Lancet Neurol, 5:148–157.  
39. Horiuchi Y., Arai M., Niizato K., Iritani S., Noguchi E., Ohtsuki T., et al. 2006. A 
polymorphism in the PDLIM5 gene associated with gene expression and 
schizophrenia. Biol Psychiatry, 59: 434-439.  
40. ICHD, Headache Classification Subcommittee of the International Headache 
Society. 2013. The International Classification of Headache Disorders: 3rd edition. 
Cephalalgia, 33: 629-808. 
 52 
41. Iwamoto K., Kakiuchi C., Bundo M., Ikeda K., Kato T. 2004. Molecular 
characterization of bipolar disorder by comparing gene expression profiles of 
postmortem brains of major mental disorders. Mol Psychiatr, 9:406-416. 
42. Jiang Y., Wu R., Chen C., You Z.F., Lou X., Wang X.P. 2015. Six novel rare non-
synonymous mutations for migraine without aura identified by exome sequencing. 
Journal of Neurogenetics, 29: 188-94.  
43. Joutel A., Ducros A., Vahedi K., Labauge P., Delrieu O., Pinsard N., et al. 1994. 
Genetic heterogeneity of familial hemiplegic migraine. Am. J. Hum. Genet, 55: 
1166-1172. 
44. Kaunisto M.A., Kallela M., Hämäläinen E., Kilpikari R., Havanka H., Harmo H, 
Nissilä M et al., 2006. Testing variants of the MTHFR and ESR1 genes in 1798 
Finnish individuals fails to confirm the association with migraine with aura. 
Cephalalgia, 26, 1462-1472. 
45. Kojić Z. and Stojanović D. 2013. Pathophysiology of migraine – from molecular 
to personalized medicine. Med Pregl, LXVI: 53-57.  
46. Krymchantowski A.V., da Cunha Jevoux C. 2014. Wine and Headache. 
Headache, 54: 967-975. 
47. Leonardi M., Steiner T.J., Scher A.T., Lipton R.B. 2005. The global burden of 
migraine: measuring disability in headache disorders with WHO’s Classification 
of Functioning, Disability and Health (ICF). J Headache Pain, 6: 429-440. 
48. Levin M. 2008. Comprehensive review of headache medicine. Oxford University 
Press, p. 59-72. 
49. Lin Q.F., Fu X.G., Yao L.T, Yang J., Cao L.Y., Xin Y.T., Hou J.X., Ye L.F.Y., 
Huang G.B. 2015. Association of genetic loci for migraine susceptibility in the she 
people of China. The Journal of Headache and Pain, 16: 553. 
50. Lippi G., Mattiuzzi C., Meschi T, Cervellin G., Borghi L. 2014. Homocysteine 
and migraine. A narrative review. Clinica Chimica Acta, 433: 5-11.  
51. Lipton R.B., Bigal M.E., Diamond M., Freitag F., Reed M.L., Stewart W.F. 2007. 
Migraine prevalence, disease burden, and the nee for preventive therapy. 
Neurology, 68: 343-349. 
52. Liu A., Menon S., Colson N.J., Quilan S., Cox H., Peterson M., Tiang T., Haupt 
L.M., Lea R.A., Griffiths L.R. 2010. Analysis of the MTHFR C677T variant with 
migraine phenotypes. BMC Research Notes, 3: 213-219. 
53. Liu R., Geng P., Ma M., Yu S., Yang M., He M., Dong Z., Zhang W. 2014. 
MTHFR C677T polymorphism and migraine risk: A meta-analysis. Journal of 
Neurological Sciences, 336: 68-73. 
54. Liu Z., Liu W., Xiao Z., Wang G., Yin S., Zhu F., et al. 2008. A major single 
nucleotide polymorphism of the PDLIM5 gene associated with recurrent major 
depressive disorder. J Psychiatry Neurosci, 33: 43-46.  
55. Liu Z., Zhu F., Yao L., Yang C., Xiao L., Zhu J. et al. 2013. PDLIM5 gene 
polymorphisms and short term antidepressant response in Chinese major 
depressive disorders. Int J Clin Exp, 6: 677-682. 
56. Lorenz A.L., Kahre T., Mihailov E., Nikopensius T., Lotman E.M., Metspalu A., 
Kolk A. 2014. Are methylenetetrahydrofolate reductase (MTHFR) gene 
polymorphisms C677T and A1298C associated with higher risk of pediatric 
migraine in boys and girls? J. Biomedical Science and Engineering, 7: 464-472. 
57. MacGregor A. 1999. Migraine in women. London, Martin Dunitz, p. 2-9.   
58. Maeno-Hikichi Y., Chang S., Matsumura K., Lai M., Lin H., Nakagawa N., 
Kuroda S., Zhang J. 2003. A PKCε-ENH-channel complex specifically modulates 
N-type Ca2+ channels. Nature Neuroscience, 6: 468-475. 
59. Maturana A.D., Nakagawa N., Yoshimoto N., Tatematsu K., Hoshijima M., 
Tanizawa K., Kuroda S. 2011. LIM domains regulate protein kinase C activity: A 
novel molecular function. Cellular Signalling, 23: 928-934. 
60. Mulder E.J., van Baal C., Gaist D., Kallela M., Kaprio J., Svensson D.A., Nyholt 
D.R., Martin N.G., MacGregor A.J., Cherkas L.F, Boomsma D.I, Palotie A. 2003. 
 53 
Genetic and environmental influences on migraine: a twin study across six 
countries. Twin Res 6: 422-431. 
61. Nattero G., De Lorenzo C., Biale L., Allais G., Torre E., Ancona M. 1989. 
Psychological aspects of weekend headache sufferers in comparison with migraine 
patients. Headache, 29: 93-99. 
62. Newton P.M., Messing R.O. 2010. The substrates and binding partners for protein 
kinase C ε. Biochemical Journal, 427: 189-196. 
63. Ng-Mak D.S., Fitzgerald K.A., Norguist J.M., Banderas B.F., Nelsen L.M., Evans 
C.J., Healy C.G., Ho T.W., Bigal M. 2011. Key concepts of migraine postdrome: a 
qualitative study to develop a post-migraine questionnaire. Headache, 51: 105-
117. 
64. Obeid R., Fassbender K., Herrmann W. 2008. Evaluation of the current evidence 
on hyperhomocysteinemia in neurological diseases. US Neurology, 4: 7-11. 
65. Pawson A.J. 1998. Protein Modules in Signal Transduction. Springer Science & 
Business Media, p. 107. 
66. Pelzer N., Stam A.H., Haan J., Ferrari M.D., Terwindt G.M. 2013. Familial and 
sporadic hemiplegic migraine: diagnosis and treatment. Current Treatment options 
in Neurology, 15: 13-27. 
67. Persico A.M., Verdecchia M., Pinzone V., Guidetti V. 2015. Migraine genetics: 
current findings and future lines of research. Neurogenetics, 16:77-95. 
68. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M., et al. 2007. PLINK: 
A tool set for Whole-genome association and population-based linkage analysises. 
American Journal of Human Genetics, 81: 559-575. 
69. Ran C., Graae L., Magnusson P.K.E., Pedersen N.L., Olson L., Belin A.C. 2014. 
A replication study of GWAS findings in migraine identifies association in a 
Swedish case-control sample. BMC Medical Genetics.  
70. Raouf R., Quick K., Wood J.N. 2010. Pain as a channelopathy. The Journal of 
Clinical Investigation, 11: 3745-3752. 
71. Reimann F., Cox J.J., Belfer I., Diatchenko L., Zaykin D.V. et al. 2010. Pain 
perception is altered by a nucleotide polymorphism in SCN9A. PNAS, 107: 5148-
5153. 
72. Rhoades R.A., Bell D.R. 2009. Medical Physiology: Principles for clinical 
medicine. 3rd edition. Lippincott Williams & Wilkins, p. 42-44 
73. Rizzoli P. 2013. Preventative pharmacotherapy in migraine. Headache, 54: 364-
369. 
74. Rocha-Filho P.A.S., Santos P.V. 2014. Headaches, Quality of life and Academic 
performance in schoolchildren and Adolescents. Headache 54:1194-1202.  
75. Rowland L.P. 1995. Merritt’s Textbook of Neurology. 9th edition. Williams & 
Wilkins, p. 837-838. 
76. Rudkjobing L.A., Esserlinf A-L., Olsen J. 2012. Future possibilities in migraine 
genetics. J Headache Pain, 13: 505-511. 
77. Russell M.B., Ducros A. 2011. Sporadic and familial hemiplegic migraine: 
pathophysiological mechanisms, clinical characteristics, diagnosis, and 
management. The Lancet Neurology, 10:457-470. 
78. Russell M.B., Iselius L., Olesen J. 1996. Migraine without aura and migraine with 
aura are inherited disorders. Cephalalgia, 16: 305–309. 
79. Russell M.B., Iselius L., Olsen J. 1995. Inheritance of migraine investigated by 
complex segregation analysis. Hum Genet. 96: 726-730. 
80. Russell M.B., Ulrich V., Gervil M., Olesen J. 2002. Migraine without aura and 
migraine with aura are distinct disorders. A population-based twin survey. 
Headache, 42: 322-336. 
81. Saeedi S., Owji A.A., Ansari M., Ghafarpour M., Ebrahimi A., Fallah M.S. 2015. 
MTHFR gene polymorphisms and susceptibility to migraine attacks. Archives of 
Medical Laboratory Sciences, 2: 61-66. 
82. Samaan Z., Gaysina D., Cohen-Woods S., Craddock N., Jones L. et al. 2011. 
 54 
Methylenetetrahydrofolate reductase gene variant (MTHFR C677T) and migraine: 
a case-control study and meta-analysis. BMC Neurology, 11: 66-75. 
83. Sarrouilhe D., Dejean C., Mesnil M. 2014. Involvement of gap junction channels 
in the pathophysiology of migraine with aura. Frontiers in Physiology, 5: 1-11. 
84. Sheikh H.U., Mathew P.G. 2012. Acute and preventive treatment of migraine 
headache. Techniques in regional anesthesia and pain management, 16: 19-24. 
85. Sherwood J., Jones T. 2011. Current treatments and research in the management of 
acute migraine attacks. The Pharmaceutical Journal, 287: 581. 
86. Shirai Y., Adachi N., Saito N. 2008. Protein kinase C ε: function in neurons. FEBS 
J, 275: 3988-3994.  
87. Shyti R., de Vries B., van den Maagdenberg A. 2011. Migraine genes an the 
relation to gender. Headache: 51: 880-890. 
88. Sintas C., Fernandez-Morales J., Vila-Pueyo M., Narberhaus B., Arenas C., et al., 
2014. Replication study of previous migraine genome-wide association study 
findings in a Spanish sample of migraine with aura. Cephalalgia, 35:776-782. 
89. Stewart W.F., Staffa J., Lipton R.B., Ottoman R. 1997. Familial risk for migraine: 
A population-based study. Ann Neurol, 41: 166-172. 
90. Striessnig J. 2005. Pathophysiology of migraine headache: Insight from 
pharmacology and genetics. Drug Discovery Today: Disease Mechanisms, 2: 453-
462. 
91. Stuart S., Cox H.C., Lea R.A., Griffiths L.R. 2010. The role of the MTHFR gene 
in migraine. Headache, 52: 515-520. 
92. Svensson D.A., Larsson B., Waldenlind E., Pedersen N.L. 2002. Genetic and 
environmental influences on expression of recurrent headaches as a function of the 
reporting age in twins. Twin Res, 5:277-286. 
93. Ulrich V., Gervil M., Kyvik K.O., Olsen J., Russell M.B. 1999. Evidence of a 
genetic factor in migraine with aura: A population-based Danish twin study. 
Annals of Neurology, 45: 242-246. 
94. Victor T.W., Hu X., Campbell J., White R.E., Buse D.C., Lipton R.B. 2009. 
Association between migraine, anxiety and depression. Cephalalgia, 30: 567-575.  
95. Vohnout B., Arnout J., Krogh V., Donati M.B., de Gaetano G., Iacoviello L. 2011. 
Association between MTHFR C677T genotype and circulating folate levels 
irrespective of folate intake: data from the IMMIDET Project. Nutrition, 2: 1209-
1210. 
96. Vries B.J., Frants R.R., Ferrari M.D. 2009. Molecular genetics of migraine. Hum 
Genet, 126: 115-132. 
97. Waldman S.D. 2011. Pain management. 2nd edition. Elsevier Saunders, p. 420-
427. 
98. Waszkielewicz A.M., Gunia A., Szkaradek N., Sloczynska K., Krupinska S., 
Marona H. 2013. Ion channels as drug targets in central nervous system disorders. 
Current Medicinal Chemistry, 20: 1241-1285. 
99. Welch K.M. 2005. Brain hyperexcitability: The basis for antiepileptic drugs in 
migraine prevention. Headache, 45(Suppl 1): S25-S32. 
100. Winner P., Lewis D., Rothner A.D. 2008. Headache in children and adolescents. 
Second edition. BC Decker Inc, p. 6-7. 
101. Yan J. and Dussor. G. 2014. Ion channels and migraine. Headache, 54:619-639. 
102. Yokoyama C.T., Myers S.J., Fu J., Mockus S.M, Scheuer T., Catterall W.A. 2004. 
Mechanism of SNARE protein binding and regulation of Cav2.2 channels by 
phosphorylation of the synaptic protein interaction site. Mol Cell Neurosci, 28: 1-
17. 
103. Zain M.A., Jahan S.N., Reynolds G.P., Zainal N.Z., Kanagasundram S., Mohamed 
Z. 2012. Peripheral PDLIM5 expression in bipolar disorder and the effect of 
olanzapine administration. BMC Medical Genetics, 13: 91-98. 
104. Zamponi G.W., Currie K.P.M. 2013. Regulation of Cav2 calcium channels by G 
protein coupled receptors. Biochimica et Biophysica Acta, 1828: 1629-1643. 
 55 
105. Zhao T., Liu Y., Wang P., Li S. et al. 2009. Positive association between the 
PDLIM5 gene and bipolar disorder in the Chinese Han population. J Phychiatry 
Neurosci, 34: 199-204. 
106. Zorina-Lichtenwalter K., Meloto C.B., Khoury S., Diatchenko L.B. 2016. Genetic 
predictors of human chronic pain conditions. Neuroscience, article in press. 
107. Zupping R. 1988.  Peavalu. Tartu Riiklik Ülikool, p. 10. 
108. Zupping R. 1998. Migreen. Trükkal, p.15-17. 
 
WEBPAGES 
http://genetics.bwh.harvard.edu/pph2/ 
http://sift.jcvi.org/ 
http://www.uniprot.org/ 
http://www.genecards.org/ 
http://string-db.org/cgi/network.pl?taskId=baVJXHRsRgzD 
http://www.ebi.ac.uk/interpro/protein/Q96HC4 
http://www.migrainebuddy.com/migrainesymptoms-the-stages-of-a-
migraine/?utm_content=buffera6c24&utm_medium=social&utm_source=twitter.com
&utm_campaign=buffer 
http://primer3.ut.ee/ 
https://pedigree.progenygenetics.com/ 
http://www.ensembl.org/info/docs/api/variation/variation_tutorial.html 
http://www.mutationtaster.org/
 56 
ACKNOWLEDGEMENTS 
I would like to express my greatest gratitude to my supervisor Anneli Kolk, 
who has throughout three years inspired, supported and encouraged me without which 
my scientific work would have been possible. She has shared her knowledge, advice 
and guidance due to which she has expanded my interest in migraine genetics 
enormously. I am grateful for her patience, motivation and wonderful cooperation.  
I would also like to thank my other supervisor Prof. Andres Metspalu, who has 
helped me tremendously with his knowledge and support.  
Furthermore I would like to thank researcher Tiit Nikopensius, who has 
unconditionally helped me with his advice, on-point comments and support. His 
expertise and readiness to answer all my questions any time has had an immeasurable 
value to me.  
Also I like to thank Eva Mekk, Kristi Läll, Silva Kasela, Steven Smit for the 
assistance and guidance.   
 57 
SUPPLEMENTS  
 
Supplement 1. Four types of visual aura. 1 – Mostly one-sided loss of perception; 2 – positive scotoma, local perception of additional structures; 3 – Negative scotoma, loss 
of awareness of local structures; 4 – Enhancements reminiscent of a zigzag fort structure. 
(http://www.halinaking.co.uk/Location/Yorkshire/Frames/Health/Migraine/Migraine%20Auras.htm) 
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SNP Gene Chromosome Position Minor allele MAF OR (95% CI) Migraine subtype Reference 
rs2651899 PRDM16 1 3,070,572 C 0.43 1.13 (1.08-1.18) Both subtypes Chasman et al., 2011; Ran et al., 2014. 
rs10915437 near AJAP1 1 4,082,866 G 0.36 0.86 (0.82-0.91) Both subtypes Anttila et al., 2013 
rs12134493 near TSPAN2 1 115,479,469 A 0.46 1.14 (1.10-1.18) Both subtypes Anttila et al. 2013;  Sintas et al., 2014. 
rs2274316 MEF2D 1 154,712,866 C 0.37 1.07 (1.04-1.09) Both subtypes, MO 
Anttila et al., 2013; 
Freilinger et al., 2012.  
rs11172113 LRP1 12 55,813,550 C 0.41 0.9 (0.86-0.94) MO Chasman et al., 2011 
rs13208321 FHL5 6 96,967,075 A 0.22 1.18 (1.13-1.24) MO Anttila et al., 2013. 
rs10504861 near MMP16 8 89,617,048 T 0.16 0.86 (0.81-0.90) MO Anttila, et al., 2013;  Sintas et al., 2014 
rs6478241 ASTN2 9 118,292,450 A 0.38 1.16 (1.11-1.22) Both subtypes Anttila et al., 2013 
rs10166942 TRPM8 2 234,489,832 C 0.19 0.86 (0.81-0.91) Both subtypes Chasman et al., 2011 
Supplement 2. Different genes identified through GWAS. MAF – minor allele frequency, OR – odds ratio; all migraine – no specification for migraine type; MO – migraine 
without aura; both subtypes – includes migraine with aura as well as migraine without aura.  
 
  MTHFR rs1801133 (C677T)  MTHFR rs1801131 (A1298C) 
  CT vs CC TT vs CC AC vs AA CC vs AA 
  OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
All migraines 1.07 (0.73-1.58) 0.767 0.8 (0.39-1.79) 0.704  1.24 (0.77-2.01) 0.394 1.83 (0.77-4.33) 0.173  
  
   
    
  
  
Migraine with aura 0.73 (0.35-1.54) 0.454 0.99 (0.25-3.75) 1  1.23 (0.59-2.54) 0.712 0.88 (0.16-4.92) 1  
  
   
    
  
  
Migraine without 
aura 1.51 (0.81-2.83) 0.205  0.94 (0.27-3.26) 1  1.25 (0.66-2.38)  0.517 2.42 (0.86-6.79)  0.103 
Supplement 3. The association between C677T and A1298C polymorphism and migraine. OR – odds ratio, CI – confidence interval. 
 
 
 
THE PROTOCOL FOR DNA EXTRACTION 
First day: 
1.     4 ml of blood placed in 15 ml centrifuge tube. Add 8 ml of A-lysis buffer (RBC), shake and 
place it on ice for 30 minutes 
2.     Centrifuge at 3100 rpm for 15 minutes (4°C) 
3.     Discard supernatant, add 8 ml of A-lysis buffer (RBC) again 
4.     Centrifuge at 3100 rpm for 15 minutes (4°C) 
5.     Discard supernatant and add 1,6 ml of TKM1, shake briefly and add straight away 100 ml of 
25% NP-40, mix thoroughly 
6.     Place the tube in -20°C overnight 
Second day: 
1.     Slowly melt the tube and centrifuge at 3100 rpm for 15 minutes 
2.     Discard supernatant and add 1,6 ml of TKM2, pipette slowly to form a homogeneous 
mixture. Add 80 ml of 10% SDS and finally 0.8 ml of TKM2. Pipette to form homogeneous 
mixture 
3.     Place tube in thermostat at 56°C for 20 minutes 
4.     Add quickly 800 ml 5M NaCl, pipette to form homogenous mixture 
5.      Centrifuge at 3100 rpm for 15 minutes 
6.     Pour supernatant to previously prepared 50 ml tube, where is 2,5 volumes of cold (-20°C) 
96% ETOH 
7.     Formed DNA clot spin around stick (e.g Pasteur pipette) and place it in ~1,5 ml of cold 70% 
ETOH 
8.     Place the stick upwards for air-drying 
9.     Dissolve the DNA in TE (~300 , ml), let it dissolve at end-over  at least for 24 hours 
 REAGENTS 
TKM1:  
10 ml of 1M TrisHCl 
10 ml of 1M KCl 
5 ml of MgCl2 
4 ml of 0.5M EDTA 
 MQ 
TKM2: 
25 ml 5M NaCl 
TKM1 till 200 ml 
25% NP-40 (nonident):  
25 g of NP-40 
MQ till 100 g 
10% SDS 
5M NaCl 
Supplement 4. The extraction protocol for DNA. 
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Primary denaturation  95°C 15 min 
denaturation 95°C 30 sec 
binding of primers 62°C 30 sec 
DNA synthesis 72°C 40 sec 
   5 cycles using touchdown method 
denaturation 95°C 30 sec 
binding of primers 59°C 30 sec 
DNA synthesis 72°C 40 sec 
   35 cycles 
Final elongation 72°C 10 min 
Supplement 5. The PCR program for Sanger sequencing. 
 
   
Supplement 6. Agarose gel electrophoresis of genomic DNA. 
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